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Abstract of thesis 
 
The current tuberculosis (TB) vaccine, live Mycobacterium bovis bacille 
Calmette-Guérin (BCG), is not efficacious in controlling adult pulmonary disease. Its lack 
of efficacy in humans is proposed to be due to factors such as the pre-exposure of hosts to 
environmental mycobacteria, the host genetic background and the intrinsic properties of 
the BCG vaccine. It can also cause pathogenicity in the immunocompromised and 
prevents the use of tuberculin in TB case-diagnosis. Development of a subunit TB 
vaccine based on a single peptide from the immunogenic protein Ag85B was studied in 
this project. Dendritic cells (DCs) are antigen-presenting cells that drive T cell responses 
in TB. The integrin-binding arginine-glycine-aspartic acid (RGD) motif was linked to the 
N-terminus of the Ag85B peptide vaccine for targeting cells expressing integrins. First, its 
immunological effects were compared against the unmodified peptide using bone-marrow 
differentiated DCs in vitro. Studies on peptide uptake by DCs, peptide processing, 
production of a Th1-polarising cytokine interleukin-12, DC migration and apoptosis were 
performed. The RGD-Ag85B peptide was taken up more efficiently, processed by both 
major histocompatibility complex (MHC) class I and II pathways and induced a higher 
level of IL-12 production. In subsequent murine immunisation experiments, the peptide 
vaccine was introduced subcutaneously with a Th1-inducing adjuvant, after a prior two-
dose fms-like tyrosine kinase ligand (Flt3L) immunisation to increase the DC population 
in vivo.  There was a relatively higher level of T cell proliferation, and interferon-gamma 
production, as well as significant induction of antigen-specific T cells, and increase in 
CD4 and CD8 T cell proportions, compared to unimmunised or Ag85B peptide-
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immunised mice. This suggests that the strategy investigated may be a useful way of 
improving subunit vaccine immunogenicity. 
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Chapter 1: Introduction and project overview 
 
 
Tuberculosis (TB), caused by the intracellular bacterium, Mycobacterium 
tuberculosis (Mtb), is one of the worlds leading infectious diseases resulting in 2  3 
million deaths annually.  Antimicrobial treatment has been available for several decades 
but it is lengthy, with a normal short-course treatment regimen involving multiple drugs 
and lasting a minimum of 6 months. Non-compliance is common and implementation 
difficult in developing countries (Kaufmann et al. 2005). Therefore, vaccines may be the 
best way to eradicate this disease.  
The only currently available vaccine is bacille Calmette-Guérin (BCG), an 
attenuated strain of Mycobacterium bovis. While BCG is effective in the protection of 
infants from severe and disseminated forms of TB, immunity declines within 1  2 
decades, and it is less effective against adult pulmonary disease which is the most 
common form of tuberculosis (Fine 1989; Rodrigues et al. 1993; Colditz et al. 1994). 
Booster doses have been proven ineffective (Karonga Prevention Trial Group 1996). The 
complete lack of protection in certain localities has been attributed to prior human 
exposure to environmental mycobacteria which can prime responses that limit BCG 
replication (Palmer et al. 1966; Demangel et al. 2005). Being a live organism, BCG can 
cause serious disease in immunocompromised patients. In addition, tuberculin skin test 
reactivity attributable to BCG diminishes the usefulness of this clinical test for diagnosis 
of early Mtb infection. A subunit vaccine can potentially overcome most of these 
disadvantages of live BCG.  
Mtb is an intracellular pathogen, thus all TB vaccines aim to generate 
antigen-specific memory T cells. Activated macrophages and dendritic cells (DCs) are the 
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key antigen-presenting cells (APCs) involved in mobilisation of T cells. DCs can engulf 
apoptotic vesicles released from infected macrophages which have died, becoming 
activated in this process. They can thus prime potent T cell responses via both major 
histocompatibility complex Class I and II pathways for both CD4+ and CD8+ T cell 
activation (Marland et al. 1996), and influence the polarisation of T cell subsets (de Jong 
et al. 2005). Thus, the study of how to engage DCs to recognise, take up and present the 
vaccine antigen appropriately to T cells is crucial in TB vaccine design.  
This study is focused on a subunit TB vaccine based on a single epitope from the 
highly immunogenic Ag85 complex, a family of secreted proteins found in Mtb, M. bovis 
BCG and many other Mycobacterium species (Harth et al. 1996). Studies with Ag85A 
and Ag85B have shown induction of strong T cell responses in most individuals infected 
with Mtb or M. leprae and in BCG-vaccinated mice and humans (Huygen et al. 1992; 
Launois et al. 1994). Studies involving the vaccination of mice with DNA vaccines 
encoding Ag85A and Ag85B and subsequently challenged with Mtb have also indicated 
that both antigens confer significant protection against mycobacterium replication in the 
lungs (Lozes et al. 1997). Thus, Ag85 complex proteins are attractive candidates as 
protective antigens. Epitope mapping studies have identified immunodominant regions of 
Ag85B (Mustafa et al. 2000; D'Souza et al. 2003). The specific Ag85B100-118 epitope is 
studied in this project as it is promiscuously recognised by multiple Human leuokocyte 
antigen (HLA) types (Valle et al. 2001; D'Souza et al. 2003). 
 It is well known that peptides are less immunogenic than whole bacteria. To 
circumvent this problem, the vaccine approach in this study combines three immune- 
enhancing strategies. It was hypothesised that targeting the peptide vaccine to DCs will 
enhance its uptake. Addition of an integrin-binding motif arginine-glycine-aspartate 
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(RGD) to peptide sequences has been shown to enhance immune responses upon 
immunisation, and also has an adjuvanting effect (Yano et al. 2003; Yano et al. 2005). 
However, the specific effect of an RGD-linked peptide on DCs has not been studied. 
Expansion of DCs prior to immunisation (for other vaccines) has been achieved in mice 
and humans by administering fms-like tyrosine kinase ligand (Flt3L), a haematopoietic 
cytokine (Maraskovsky et al. 1996). Hence, this study combines these two approaches, 
together with a newly developed Th1-inducing adjuvant (Holten-Andersen et al. 2004; 
Rosenkrands et al. 2005) tested for TB proteins, trehalose 6,6′-dibehenate/dimethyl 
dioctadecyl ammonium bromide (TDB/DDA), in the design of our vaccination strategy.  
Our first aim was to elucidate how RGD-mediated DC targeting of the 
immunogenic peptide influences DC behaviour. To this end, murine bone marrow DC 
uptake of the peptide, migration, apoptosis, antigen presentation and production of 
IL-12(p70) cytokine were measured. The second aim was to analyse the cell-mediated 
immune response to vaccination in naïve mice. Helper T cell activation, proliferation, 
production of Th1 inducing cytokines (IL-12(p70) and IFN-γ) and IL-2 induced in 
immunised mice were examined after immunisation of Balb/c mice. The outcomes of this 
work are relevant to understanding the immune effects of adding RGD in the design of 
peptide vaccines, as well as contributing to the current global efforts to design a new TB 
vaccine.   
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Chapter 2: Literature review 
 
 
2.1 Tuberculosis: scale of the problem 
 
Tuberculosis (TB) is a bacterial infection caused by the respiratory pathogens 
Mycobacterium tuberculosis, Mycobacterium bovis, or Mycobacterium africanum. 
Although the lungs are frequently the primary organ involved (pulmonary TB), TB can 
also affect the central nervous system, lymphatic system, circulatory system, 
genitourinary system, bones, joints and the skin (Raviglione MC 2004). The disease 
continues to be a leading cause of death worldwide (WHO 2008). Approximately 
one-third of the worlds population is infected with Mtb, an estimated two billion people 
annually. Not every infected individual will develop the disease, the majority have 
asymptomatic or latent disease. Approximately one in ten asymptomatic patients will 
develop active disease. If left untreated, TB will result in death in more than 50% of 
patients with active disease  about two million people succumb to the disease annually 
(Kaufmann et al. 2005),  predominantly in developing countries (Enarson et al. 1999).  
Anti-mycobacterium drugs are available, but treatment is lengthy (Glynn et al. 2002). To 
maintain compliance, continuous patient surveillance must be performed by trained 
medical personnel and this is difficult where infrastructure is poorly developed. The 
emergence of the HIV/AIDS epidemic will fuel the current global TB epidemic, with the 
World Health Organisation (WHO) estimating that more than a billion people will be 





2.2 Control measures for tuberculosis  
 
Present control measures for tuberculosis rely on discoveries that have been made 
in the past century. These measures include the administration of BCG as a vaccine and 
the use of anti-microbial drugs. Acid-fast staining of sputum samples and skin testing 
with tuberculin (PPD, purified protein derivative of Mtb) are two techniques usually 
employed in the diagnosis of tuberculosis. These were developed by Robert Koch in 1882 
and 1890 respectively. The BCG vaccine was developed jointly by Albert Calmette and 
Camille Guérin between 1906 and 1919 and was first given in 1921. New molecular 
techniques which detect T cell reactivity to Mtb specific-antigens not found in BCG help 
to identify latently infected healthy TB contacts for targeting prophylactic treatment 
(Gerald H. Mazurek 2003).The first drug against tuberculosis, streptomycin, was 
discovered by Wakman in 1945, followed later by isonazid, rifampicin, pyrazinmamide 
and ethambutol, but all the drugs have significant side-effects (CDC 2003). The WHO 
recommends directly observed therapy (DOT), a system where TB patients are observed 
by medical personnel when taking their daily dose of antibiotics for 6 months, to improve 
patient adherence with tuberculosis therapy (WHO 2008).The emergence of multidrug-
resistant tuberculosis (MDR-TB) cases and extensively resistant tuberculosis (XDR-TB) 
has increased failure rates and cost of treatment (Reece et al. 2007). This has led to 
interest in the development of more effective TB vaccines.  
 
2.3 Host response to tuberculosis 
 
Mtb is an intracellular pathogen which has developed sophisticated mechanisms 
of survival within host macrophages, including preventing recognition of infected 
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macrophages by T cells by inhibiting MHC class II processing and presentation, evading 
macrophage killing mechanisms, such as those mediated by reactive nitrogen 
intermediates and phagolysosome fusion (Flynn et al. 2003). Following aerosolisation 
from coughing by an infected person, Mtb will first enter the lungs, and multiply in the 
alveolar macrophages and epithelial cells. Subsequently, DCs and monocytes may carry 
the bacilli to the draining lymph nodes which can become highly inflamed. Waves of 
activated CD4 and CD8 T cells traffic back into the lungs and wall off infected 
macrophages in granulomas (Flynn et al. 2005). Inflammatory cytokines are secreted and 
much tissue necrosis may occur within these foci of infected cells, and the granulomas are 
caseous in advanced form. As the bacilli are resistant to several microbicidal mechanisms 
within macrophages, some will multiply intracellularly even as the macrophages die, 
releasing more bacilli which may spread via blood or lymphatics to various parts of the 
body. The bacilli within granulomas or lung epithelial cells can also become dormant 
(latent tuberculosis) in a state of dynamic balance with the hosts immunity, until years 
later when they could resume multiplication to cause active disease, perhaps due to 
weakening of host immunity related to ageing or immunosuppression from HIV infection 
or cancer drug therapies (Saunders et al. 2007). 
In Mtb infection, several subsets of T cells are stimulated. These include the 
conventional MHC class II restricted CD4 T cells, the MHC class I restricted CD8 T 
cells, unconventional T cells such as γ/δ T cells which recognise non-proteinaceous 
phosphorylated ligands (Kaufmann 1996) and glycolipid-specific CD1 restricted T cells 
(Fischer et al. 2004).  Studies using gene knock-out mice have shown that both CD4 and 
CD8 T cell subsets are critical for protection against the disease (Flynn et al. 1992; 
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Cooper et al. 1993; Flynn et al. 1993). In addition, a Th1 response is critical for the 
containment of the infection whereas progressive TB may be associated with increased 
Th2 responses (Bottasso et al. 2007). One of the main roles of interferon gamma (IFN-γ) 
and tumour-necrosis factor alpha (TNF-α) is to aid in activation of macrophages, which 
control bacterial proliferation by increasing fusion of the phagosome with the lysosome 
(Schaible et al. 1998; MacMicking et al. 2003). Activated macrophages wall off Mtb 
inside granulomatous lesions (Kaufmann 2001). Hence, individuals with deficient IFN-γ 
signalling suffer from rapid evolution of the disease (Jouanguy et al. 1996; Newport et al. 
1996) , TNF-α deficient mice do not form organised granulomas (Kindler et al. 1989; 
Bean et al. 1999; Chakravarty et al. 2008) and treatment of latently infected patients with 
anti-TNF-α antibodies causes TB reactivation (Maini et al. 1999).  
 
2.4 Tuberculosis vaccines 
 
There are several stages of disease at which a TB vaccine could be useful. There is 
a need for a prophylactic vaccine to prevent primary infection, a therapeutic vaccine to 
act as an adjunct to chemotherapy for those with active disease, and a vaccine for the 
latently infected host to prevent reactivation. Accordingly, various new pre- and post-
exposure TB vaccine approaches have been considered by others in the field. Some of 
these strategies seek to incorporate BCG in infancy to prime the host, to be followed 




BCG, an attenuated strain of M. bovis, is the only licensed vaccine against 
tuberculosis (Sterne et al. 1998). It was generated in the early 20th century by continual 
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passage of virulent M. bovis (the causative agent of TB in cattle) using both in vitro 
culture methods and in experimental animals (Reece et al. 2007). The vaccine has been 
included since 1974 in the WHO Expanded Program on Immunisation (WHO 1974) and 
is one of the worlds most commonly administered human vaccines, as it is relatively safe 
and inexpensive (Reece et al. 2007). It is typically given intradermally as a single dose to 
newborn infants. The review of many studies suggests that administration of BCG 
vaccine has been associated with a decline in TB meningitis and disseminated disease in 
childhood, with reported efficacy ranging from 46-100% (Girard et al. 2005) . However, 
its effects on adult vaccinees have been widely disparate in different trials and in some 
areas, had no impact at all in reducing the incidence of adult pulmonary disease (Colditz 
et al. 1994). The efficacy of neonatal BCG vaccination also wanes with age, in one study 
from 82% (persons aged < 15 years) to 20% (persons aged > 25 years) (al-Kassimi et al. 
1995). In addition, BCG apparently only protects against primary infection and cannot 
help those with early infection (ten Dam et al. 1982), individuals that have been sensitised 
with environmental bacteria (Palmer et al. 1966; Fine 1995), patients with latent TB or 
individuals with prior BCG vaccination (Fine 1995; Karonga Prevention Trial Group 
1996).  
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BCG has failed to control the global increase of new TB cases after one century of 
usage. This has been blamed on the failure of BCG to elicit long-lasting T cell memory. 
New approaches aim to improve on this. New TB vaccine approaches can be broadly 
divided into the live attenuated vaccines (e.g. rationally attenuated strains of Mtb, 
recombinant BCG and live vectors expressing genes coding for immunodominant 
mycobacterial antigens) and the subunit vaccines (e.g. immunogenic proteins or peptides 
in adjuvants and DNA vaccines) (Girard et al. 2005).  
 However, although BCG has variable protective efficacy in humans against TB, it 
still remains the current gold standard in murine vaccine testing because it decreases the 
bacterial burden in the mice significantly. In general, in naïve mice infected via the 
aerosol route with 20  100 Mtb, the bacteria will proliferate exponentially within the first 
30 days, reaching a plateau of approximately one million bacteria in the lungs until 
susceptible mice succumb at approximately 250 days after infection. However, in mice 
with prior BCG immunisation, a reduction of 90%  95% of the lung Mtb load, with 
correspondingly much less severe lung pathology, relative to naïve mice was observed (Li 
et al. 1999; Reece et al. 2007). The murine post-immunisation PPD-specific IFN-γ 
production and proliferative response induced by BCG also tends to be much higher than 
most subunit vaccines (Pym et al. 2003; Fan et al. 2007). 
 
2.4.2 New live attenuated vaccines 
 
Vaccination with live BCG confers protection against Mtb challenge in a variety 
of animal models (Blanden et al. 1969; Orme 1988). One particular study, which 
investigated vaccination with dead BCG bacteria, shows that only live BCG vaccine 
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induces the migration of acid-fast bacilli to the draining lymph node, accompanied by an 
increase in mononuclear cells in the lymph nodes and expression of inducible nitric oxide. 
The differential response generated by the dead and live BCG vaccine could explain why 
a live BCG vaccine is more efficacious (Chambers et al. 1997).  
Some reasons for BCG inefficacy could be its loss of certain immunogenic 
antigens compared to Mtb or its failure to persist in the host (Skeiky et al. 2006). On the 
basis that Mtb itself is the most effective in stimulating Mtb-specific immune responses, 
there are some candidate vaccines based on attenuated, auxotropic Mtb strains. These 
include a PhoP mutant of Mtb, which has a defective cell envelope and replicative ability 
in human and mouse macrophages (Perez et al. 2001) and double auxotrophic mutants 
which lack the ability to synthesis lipids needed for its virulence (Collins 2000; 
Sambandamurthy et al. 2002). However, safety remains a major concern and there is 
difficulty in achieving a reasonable level of attenuation without diminishing 
immunogenicity.  
Another approach is the re-engineering of BCG, based on the premise that 
enhancement of BCG efficacy can be achieved via the insertion of genes encoding either 
immunodominant antigens or immunostimulatory cytokines. Three examples of such 
recombinant BCG strains that have been more effective than wild-type BCG in protection 
against TB challenge in animal models are briefly described here. BCG30 overproduces 
the 30kDa major secreted mycobacterium protein Ag85B (Horwitz et al. 2000). In the 
BCG::RD1 strain, the RD1 genomic segment of Mtb, absent in all BCG strains, is 
reintroduced, resulting in the expression of ESAT-6 protein and other immunogenic 
factors, and as well as increasing BCG persistence (Horwitz et al. 2000; Hsu et al. 2003). 
r-BCG Hly, a novel BCG construct expressing Hly (listeriolysin, a secreted protein by 
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Listeria monocytogenes, which allows BCG to escape from the host cell phagosome into 
the cytosol) was designed with the rationale that expression of Hly by BCG will allow 
BCG antigens to enter the cytosol of the host cell, increasing CD8 T cell priming (Grode 
et al. 2005). In mice, the r-BCG Hly vaccine protects significantly better against aerosol 
infection with Mtb compared to the unmodified parental BCG strain (Grode et al. 2005). 
Non-mycobacterium live vectors have also been much studied. An example is 
expression of Ag85A via recombinant MVA (Modified Vaccinia Ankara virus). This 
vaccine has been used in a BCG-prime, MVA boost strategy, and shown efficacy 
comparable to BCG in animal models challenged with Mtb via an aerosol route 
(Goonetilleke et al. 2003). A similar BCG-prime, MVA-boost clinical trial in human 
subjects shows increase in antigen-specific IFN-γ secreting T cells significantly compared 
to subjects administered with a single BCG vaccination (McShane et al. 2004). This work 
proves the principle that Ag85 subunit vaccines are effective in boosting immunity 
primed by primary BCG vaccination. 
 
2.4.3 Subunit and vector based vaccines 
 
Live vaccines are limited by safety concerns especially in immunocompromised 
individuals, as well as technical challenges in manufacturing and reproducibility. 
Recently, the Gobal Advisory Committee on Vaccine Safety established by the World 
Health Organisation recommended that BCG should not be administered to children 
infected with HIV (Hesseling et al. 2007), yet this is a group that is vulnerable to TB 
infection. Hence, there is interest in subunit vaccines e.g. recombinant proteins, fusion 
proteins, peptides, or DNA vaccines. Subunit vaccines usually comprise of one or more 
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major Mtb antigens, delivered together with powerful adjuvants. Such antigens are 
selected on the basis of immunogenicity, high abundance or active secretion by Mtb 
during infection (Reece et al. 2007). This strategy assumes that a sufficient protective 
immune response can be constituted against a limited number of antigens. Vaccines 
designed using this approach have met with some success. For example, a variety of 
vaccines using antigens isolated from Mtb short-term culture filtrates (Horwitz et al. 
2006) such as Ag85A (Lozes et al. 1997) , Ag85B (Kamath et al. 1999) and ESAT-6 
(Brandt et al. 2000; Agger et al. 2006)  increase protection against animal aerosol 
challenge with Mtb. These subunit vaccines could either replace BCG or boost BCG-
primed immunity (Weinrich Olsen et al. 2001; Skeiky et al. 2004; Dietrich et al. 2007).  
The peptide vaccine approach has several significant advantages other than safety. 
Chemical synthesis of peptides in any sequential amino acid arrangements is rapid, 
efficient and highly reproducible in production, relative to recombinant proteins, which 
have potential problems of expression levels, purification and removal of the expression 
vehicle (Babiuk 1999). However, major histocompatibility complex (MHC) restriction in 
peptide presentation requires the selection of protein epitopes that are compatible with as 
many MHC types as possible in genetically diverse populations. Moreover, because of the 
weakly immunogenic nature of the peptide relative to live vaccines, a strong 
immunoadjuvant is usually required to maximise the immune response (Babiuk 1999).  
 
2.4.4 TB vaccine adjuvants  
 
Some adjuvants that have recently been studied for use with TB subunit vaccines 
include dimethyl dioctadecyl ammonium bromide (DDA), trehalose 6, 6′-dibehenate 
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(TDB) and IC31. DDA is a quaternary ammonium compound which has been reported as 
an effective adjuvant for eliciting cell-mediated and humoral responses for various viral 
and bacterial antigens in a number of different animal species (Hilgers et al. 1992; 
Lindblad et al. 1997; Brandt et al. 2000; Weinrich Olsen et al. 2001; Holten-Andersen et 
al. 2004). However, DDA liposomes are physically unstable and tend to aggregate in 
solutions that contain small amounts of salt or in prolonged suspension in water 
(Davidsen et al. 2005). Therefore, DDA is normally used in combination with TDB, a 
synthetic analogue of trehalose 6, 6′-dimycolate (TDM), also known as cord factor  an 
immunostimulatory component of the mycobacterial cell wall. It has reduced toxicity 
compared to TDM (Pimm et al. 1979). A study which used TDB/DDA adjuvant in 
combination with fusion protein Ag85B-ESAT-6, reported a significant increase in 
cell-mediated immunity and humoral responses with a strong Th1 response (Davidsen et 
al. 2005). IC31, an antimicrobial poly-peptide (KLKL5KLK) and a phosphodiester-
backboned oligodeoxynucleotide (ODN1a), induces potent cell-mediated responses 
characterised by the generation of high numbers of IFN-γ secreting cells (Kritsch et al. 
2005; Schellack et al. 2006). A study which used the IC31 adjuvant with Ag85B-ESAT-6 
reported efficient protection in the guinea pig aerosol model of tuberculosis (Agger et al. 
2006).   
Besides the use of chemical adjuvants, another way to enhance the 
immunogenicity of the peptide vaccine is via sequence alterations that allow retention of 
antigenic specificity while enhancing the targeting of the peptide to antigen presenting 
cells. This will be described in a later section. 
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2.5 Dendritic cells 
  
DCs are a unique set of cells that play a central role in eliciting an appropriate 
cellular immune response to pathogens. Depending on their maturation status, they are 
capable of efficient antigen uptake, antigen processing and presentation. Although 
macrophages also share the above properties, DCs are the only professional antigen-
presenting cells (APCs) able prime naive T cells efficiently (Banchereau et al. 1998). To 
effectively prime good cell-mediated responses to the vaccine antigen, appropriate DC 
activation is important (Banchereau et al. 1998).  
There are several mature and immature subsets of DCs that have been 
characterised in mice. Mature DC subsets are characterised by high expression of CD11c, 
MHCII and significant levels of the co-stimulatory molecules CD80 and CD86. They are 
also capable of efficient stimulation of T cells. Three subsets of mature splenic murine 
DCs have been identified i) CD8α+ lymphoid DCs (CD8α+CD11b−DEC205+) ii) CD8α-
CD11b−CD4+ myeloid DCs (CD8α-CD11b+DEC205- CD4+) and iii) CD8α-CD4- myeloid 
DCs (CD8α-CD11b+DEC205- CD4-). In the lymph nodes of mice, in addition to the three 
subsets mentioned there are an additional two subsets i) Langerhans-derived DCs 
(CD8αdullCD11b+DEC205- CD4-Langerine+) ii) dermal DCs (CD8α-CD11b+DEC205+ 
CD4-Langerine−). In addition to the above mature subsets, a DC subset known as the 
plasmacytoid precursor subset, has been characterised to have the phenotype 
(CD8αdullMHCIIdullB220+ CD4+ or CD8αdullMHCIIdullB220+ CD4+) (Pulendran 2004). 
 In humans, three main subsets of mature DCs have been identified in the blood: i) 
myeloid DCs (also known as interstitial or dermal DCs) (CD11c IL-3R+ high HLA-
DR+CD11b_CD13 CD33 CD4+CD1a - Birbeck granule Factor V111+ Langerin CD86+ 
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CD40+CD80+)  ii) Langerhans DCs (CD11c+IL-3R dull HLA-
DR+CD11b+CD13+CD33+CD4+CD1a Birbeck granule Factor V111+ Langerin CD86+ 
CD40+CD80+) and iii) plasmacytoid DCs (CD11c+IL-3R HLA-
DR+CD11b+CD13+CD33+CD4+CD1a+Birbeck granule+ Factor V111 Langerin+ CD86+ 
CD40+CD80+)  (Pulendran 2004). 
 
2.5.1 The role of DCs in eliciting an immune response  
 
Immature DCs are found in various epithelial sites, particularly at portals of 
microbe entry. These immature DCs express pathogen recognition receptors which enable 
them to perform as immunological sensors for various pathogens  (Pulendran 2004). 
Immature DCs express low levels of MHC class II, almost no costimulatory molecules 
and are thus poorly stimulatory and may even induce immunological tolerance. However, 
they are very efficient in capturing microbes, via both receptor-mediated as well as 
non-receptor mediated mechanisms. Migration of immature DCs first responds to the 
chemokines such as macrophage inflammatory protein 3 alpha (MIP3α or CCL20) which 
is produced by endothelial cells of the lymphatic vessels, and binds to the chemokine (C-
C motif) receptor 6 (CCR6) expressed on immature DCs. Upon activation by signals 
delivered directly by the invading microbes, indirectly in response to cell death or by 
cytokine release in the vicinity, immature DCs then downregulate their expression of 
CCR6 and express CCR7 on their cell surfaces; this is a receptor for macrophage 
inflammatory protein 3 beta (MIP3β or CCL19) which is expressed in the T cell areas of 
lymph nodes (Pulendran 2004). The chemokine CCL21, which is produced by the 
endothelial cells of lymphatic vessels and also binds CCR7, also affects migration of DCs 
from the peripheral tissues to the secondary lymphoid organs. Therefore, the migration of 
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DCs first responds to the chemokine MIP3α, then subsequently to the chemokine CCL21, 
followed by MIP3β.  This allows immature DCs which may have captured antigens to 
migrate towards the T cell areas of the draining lymph nodes. During this migration 
process, immature DCs undergo maturation, switching from their antigen-capturing and 
processing capacity to their immuno-stimulatory capabilities. Therefore mature DCs 
express high levels of class MHC II and costimulatory molecules. They present microbial 
antigens to T cells, thus initiating an appropriate immune response.  
DCs can also affect the immune response by modulating either the amplitude or 
the type of the response (Schulz et al. 2002). DCs can modulate the T cell response 
through the secretion of appropriate cytokines. For example, the secretion of IL-12(p70) 
by mature DCs (Cella et al. 1996; Koch et al. 1996) will cause the differentiation of Th1 
T cells which produce IFN-γ, allowing activation of anti-microbial activities of 
macrophages. However, if mature DCs secrete IL-4, T cells will differentiate into Th2 
cells with the secretion of IL-5 and IL-4, thus resulting in the activation of eosinophils 
and production of antibodies by B cells (Banchereau et al. 1998).  
 A unique property of DCs is their cross-priming capability. Exogenous antigen 
uptake usually results in presentation via MHC II to CD4 T cells. However, DCs may 
engulf apoptotic bodies resulting from the death of an infected cell, becoming activated 
and priming potent CD8 T cell responses via the MHC I pathway (Schaible et al. 2003; 
Winau et al. 2004). Induction of cross-priming is especially important in vaccines against 
intracellular pathogens like Mtb, which have been shown to cause apoptosis in host cells, 
thus generating apoptotic bodies (Schaible et al. 2003; Winau et al. 2004). A unique 
subset of murine DCs with this cross-priming ability has been identified; they display the 
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cell surface markers, CD11cbright, CD11bdull, CD8α, DEC205 and CD36, (Pulendran 
2004).  
Although both the CD8α- DCs and CD8α+ DC are capable of priming CD4 and 
CD8 T cells (Daro et al. 2000), in some studies it is suggested that the CD8α+ DC are less 
efficient at priming T cells compared to CD8α- DCs (Kronin et al. 1996; Suss et al. 1996). 
CD8α+ DC are unable to support cytokine production by CD8 T cells (Kronin et al. 
1996).  The CD8α+ subset is also more capable of secreting higher levels of IL-12(p70) 
than the CD8α- subset upon induction. The CD8α- DCs elicit a Th2/Th0 response and as 
such, the CD8α+ and CD8α- subsets can differentially regulate the Th1/Th2 balance 
(Maldonado-Lopez et al. 1999; Pulendran 2004).  
 
2.5.2 Dendritic cells in tuberculosis infection and vaccination 
 
DCs play a direct role in the initiation of adaptive T cell responses against Mtb. A 
delayed CD4 T cell response to Mtb is observed when DCs are depleted in vivo, thus 
resulting in impaired control of pathogen replication (Tian et al. 2005). DCs but not 
macrophages migrate specifically to the draining lymph nodes and initiate primary Th1 
responses. This has also been shown to occur following Mtb aerosol challenge of mice 
(Bhatt et al. 2004). These results indicate that DCs play a pivotal role in priming the 
primary adaptive immune response to counter Mtb infection. However, DCs are not 
required for the secondary CD4 T cell response following Mtb infection in mice 
vaccinated with an Mtb immunogenic protein (Bhatt et al. 2004). The mycobacterium-
specific lipoglycan lipoarabinomannan (LAM) ligand binds to the intercellular adhesion 
molecule-3 grabbing non-integrin (DC-SIGN) expressed by human monocyte-derved 
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DCs and this interaction is crucial for the infection of DCs (Tailleux et al. 2003). 
Immature DCs which are capable of efficient antigen uptake (Sertl et al. 1986), when 
exposed to Mtb antigens or infected by Mtb, are transformed into mature DCs with 
enhanced T cell stimulatory properties and migrate into draining lymph nodes were 
effector T cell differentiation and memory T cell expansion take place (Lanzavecchia et 
al. 2000; Kaufmann 2001; Lanzavecchia et al. 2001; Kaufmann et al. 2003). This leads to 
Mtb resistance.  
Like macrophages, DCs are also infected by mycobacteria in vivo and the 
mycobacteria can persist in the DC population up to two weeks after infection (Jiao et al. 
2002). It is not clear whether mycobacterium survival in DCs may also be due to an 
alteration of the mycobacterial phagosome similar to that in the macrophage. However, 
following infection, DCs have poor bactericidal activity, which leads to Mtb growth in 
human and murine DCs in vitro (Henderson et al. 1997; Bodnar et al. 2001). Studies seem 
to suggest that the turnover of mycobacteria within DC is not sufficient to kill the host 
cell. Following activation by IFNγ or TNFα macrophages may potentially kill all of the 
mycobacteria residing within the phagosome. However, this does not occur in DCs 
(Mohagheghpour et al. 2000; Bodnar et al. 2001; Tailleux et al. 2003; Hope et al. 2004). 
The mycobacteria appear to reside in vacuoles which are separated from the normal 
recycling pathway (Bodnar et al. 2001; Tailleux et al. 2003). One study also suggests that 
similar to macrophages (Flynn et al. 2003), antigen presentation by infected DC is rapidly 
also lost, possibly due to an escape mechanism (Jiao et al. 2002).  
Vaccination strategies designed to enhance the production of IFN-γ, such as 
co-delivery of the cytokines IL-12(p70) and IL-23 during DNA vaccination, significantly 
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improve protection against TB (Palendira et al. 2002; Wozniak et al. 2006). IL-12 is 
critical for the induction of Th1-like CD4+ cells, and humans and mice lacking the p40 
chain of IL-12 or its receptors are highly susceptible to Mtb infection (Cooper et al. 1997; 
Altare et al. 1998; de Jong et al. 1998). Mtb infection of DCs leads to polarisation of 
naïve T cells to the Th1 phenotype due to production of IL-12 (Giacomini et al. 2001; 
Hickman et al. 2002). Following murine BCG immunisation, the DC population, and not 
the macrophage population, is responsible for IL-12 production and antigen presentation 
to T cells (Jiao et al. 2002).  
 
2.6 Vaccines and DCs 
 
Since DCs play a pivotal role in recruitment of vaccine-specific T cells, there are 
efforts directed at improving the chances that DCs encounter the vaccine antigen. These 
are generally termed DC targeting strategies.  
Ex vivo approaches include the isolation of DCs from blood of patients, pulsing 
the DCs with appropriate antigens and other maturation stimuli before re-introducing the 
DCs back into the patients (Imro et al. 1999; Banchereau et al. 2005). Although this 
approach has yielded promising results for cancer therapy (Gatza et al. 2002; Timmerman 
et al. 2002; Wang et al. 2002), it is too logistically challenging, time-consuming and 
expensive for a mass vaccination programme. In vivo DC targeting strategies deliver the 
vaccine antigen directly to DCs within the host, by designing the vaccine such that it 
contains a molecule that will bind to DC surface proteins. DC surface molecules that have 
been targeted include the mannose receptor (Berney et al. 1999), DC-SIGN (Tacken et al. 
2005) and DEC-205 (Badiee et al. 2007). Free antigen, protein fusions and viral gene 
therapy have been used in this approach with good results (Reddy et al. 2006); (Davis et 
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al. 2002; Hauser et al. 2004; Mahnke et al. 2005). In the present project, an in vivo DC 
targeting approach is used, by designing the vaccine peptide linked to an N-terminus 
arginine-glycine-aspartate (RGD) motif. This interacts with integrins such as α5β1 and 
αvβ3, which have been demonstrated to be expressed on dendritic cells (Albert et al. 
1998; Ammon et al. 2000). 
 
2.6.1 Flt3L (fms-like tyrosine kinase 3 ligand) 
 
Culture of bone marrow progenitors with fms-like tyrosine kinase 3 ligand (Flt3L) 
is one method commonly used to generate DCs. Flt3L promotes development of both 
conventional DCs (cDC) and plasmacytoid DCs (pDC) (Naik et al. 2005). Upon daily 
administration of soluble Flt3L at a dose of 10 µg per dose over nine consecutive days in 
mice (Maraskovsky et al. 1996) or daily soluble Flt3L at a range of 10  100 µg/kg/day 
for 14 consecutive days in humans (Maraskovsky et al. 2000), a significant increase in the 
number of DCs in several tissues including the spleen, lymph nodes, thymus, Peyers 
patches, as well as in the circulation, lungs and liver is induced. In mice, a 17-fold 
increase in DC numbers in the spleen, 4-fold in the lymph nodes and 6-fold in the 
peripheral blood, is noted (Maraskovsky et al. 1996). In particular, it induces the 
expansion of the CD8α+, CD8α-CD4+ and CD8α-CD4- DCs as well as the dermal DCs in 
the lymph nodes, the pDC precursors but not the Langerhans cell DCs (LCDCs) in mice 
(Pulendran 2004). In humans, a 44-fold increase in CD11c+ peripheral blood DCs and a 
12-fold increase in CD11c  IL-3R + DC precursors, is noted (Maraskovsky et al. 2000). 
This increase in DCs is associated with enhanced immune responses against soluble 
protein antigens, tumours, transplants, viral antigens and DNA vaccines.  
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A recent Mtb DNA vaccine study, using a plasmid encoding Flt3L and the 
immunogenic Ag85B protein, increases protective immunity against aerosol Mtb 
infection in mice (Triccas et al. 2007). Our vaccine design strategy proposes to directly 
introduce Flt3L into mice to expand DCs before administration of a DC targeting peptide 
vaccine.  
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Dendritic cells (DCs) play a central role in the recruitment of naïve T cells, 
therefore it is important that subunit vaccines can be optimised for DC uptake. It has 
previously been shown that arginine-glycine-aspartic acid (RGD)-tagged peptides are 
preferentially directed to integrins but specifically how they affect DC behavior was 
unclear. A tuberculosis vaccine based on an immunogenic peptide of the Ag85B protein 
was designed with an N-terminus RGD motif. We investigated how the RGD-peptide 
compares with the unmodified peptide, in terms of uptake by immature DCs, processing 
and presentation, cytokine production and DC migration. The Ag85B-RGD peptide was 
taken up by DCs more efficiently in vitro, relative to the control peptide. DCs expressing 
the integrins α5β1 and αvβ3 showed proportionately greater uptake of the RGD-peptide. 
The RGD-peptide was processed by both major histocompatibility complex class I and 
class II pathways, induced more interleukin-12 production by DCs, and a stronger recall 
response upon presentation to memory T cells than control peptide. Migration of 
RGD-peptide pulsed DCs in response to chemokine signals was also relatively higher. 
Therefore, RGD-tagging of peptides may be a useful way to improve their 





 Dendritic cells (DCs) play a central role in eliciting and modulating T-cell 
mediated responses to pathogens. They process protein antigens through the major 
histocompatibility complex class (MHC) I and II pathways, and through antigen 
presentation, are required for primary activation of naïve CD4 and CD8 T cells 
(Banchereau et al. 1998). Hence, optimising DC uptake of antigens by targeting antigen 
delivery to DCs is an important strategy for developing new vaccines against infectious 
diseases for which cell-mediated immunity is required for protection (Steinman et al. 
2007).   
Several ex vivo and in vivo DC vaccine strategies have been described. The 
ex vivo approach is mainly geared towards therapeutic vaccines, and is based on ex vivo 
pulsing of autologous DCs with appropriate antigens and other maturation stimuli before 
re-introducing them back into the host. This approach has been very promising in cancer 
immunotherapy (Banchereau et al. 2005). In vivo DC targeting strategies may be 
applicable to prophylactic vaccines as well; they are largely based on directing 
immunogenic antigens to in vivo DCs, with various DC-directed antigen delivery 
methods, including using anti-DEC205 antibodies or integrin-binding bacterial toxins as 
vectors (Bonifaz et al. 2004). The ex vivo methods are logistically challenging and costly, 
but in vivo targeting methods have to contend with the low numbers of immature 
peripheral DCs available in the skin to pick up the antigen.  Hence, research on in vivo 
DC targeting has also focused on linking the delivery method with methods for 
amplifying the responses (e.g. by adjuvants) (Kool et al. 2008), protecting the antigen 
from degradation (Chikh et al. 2001) or expanding the DC population in vivo (Triccas et 
al. 2007).  
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Integrins are cell adhesion receptors that bind to extracellular matrix (ECM) 
ligands, cell surface ligands and soluble ligand molecules. They modulate the physical 
interaction between cells and the ECM, and are essential for cell adhesion, migration, 
positioning and induction of signalling events for cell survival, proliferation and 
differentiation (Berton et al. 1999). The arginine-glycine-aspartic acid (RGD) motif 
present in many ECM proteins such as fibronectin, vitronectin and other adhesive 
proteins, binds to integrins such as α1β1, α2β1, α5β1, αvβ1 and αvβ3 (Ruoslahti et al. 1987). 
Incorporation of RGD into a vaccine antigen has therefore gained interest as a method for 
targeting vaccines to DC-expressed integrins. A subset of day 7 granulocyte-macrophage 
colony-stimulating factor/ interleukin-4 (GM-CSF/IL-4) differentiated bone marrow 
derived murine DCs (30%) and fresh splenic DCs (<5%) expresses high levels of integrin 
αvβ3 (CD51/CD61). These cells are highly permissive for infection (transduction) by 
adenovirus vectors expressing RGD in the capsid, whereas CD51lo cells are not readily 
transduced. The specificity of the RGD-integrin interaction is further shown by 
abrogation of the transduction by pre-treatment of the cells with soluble RGD-peptides 
(Harui et al. 2006). In a separate study, an engineered IL-12 protein linked to a cysteine-
rich RGD peptide has been shown to be targeted specifically for cells expressing αvβ3 
integrin and promotes interferon-gamma (IFN-γ) production (Dickerson et al. 2004). In an 
infection model, addition of the RGD motif to the N-terminus of a peptide vaccine 
enhances its immunogenicity, and enables nasal immunisation without adjuvants (Yano et 
al. 2003; Yano et al. 2005). The RGD motif also contributes to human DC migration in 
response to the HIV Tat peptide, a process which is inhibited by β1 and αvβ3 integrin 
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blocking antibodies (Benelli et al. 1998). However, the specific immunological effects of 
encounter with RGD-linked peptides on subsequent DC behaviour is unknown. 
  There is much interest in development of new vaccines against Mycobacterium 
tuberculosis (Mtb) that can improve on the current vaccine bacille Calmette-Guérin 
(BCG). Ag85B, a fibronectin-binding protein, is a member of the Ag85 family of 30  
32 kDa mycolyl transferases secreted by Mtb. It is highly immunodominant, and is 
therefore among the leading candidates for inclusion in tuberculosis subunit vaccines 
(Skeiky et al. 2006). A recombinant BCG vaccine expressing Ag85B induced stronger 
protective responses against murine Mtb challenge than the conventional BCG vaccine 
(Horwitz et al. 2000). Promiscuous human T cell recognition has also been observed in 
peripheral blood mononuclear cells or T cell lines from purified protein derivative-
positive donors or BCG-vaccinated subjects (Mustafa et al. 2000; Mustafa et al. 2005). 
Ag85B epitope mapping studies have identified both murine (D'Souza et al. 2003) and 
human Th1 T-cell epitopes (Mustafa et al. 2000). The epitope Ag85B100-118 is amongst the 
most immunogenic epitopes of Ag85B, recognised by MHC Class II of Balb/c mice 
(D'Souza et al. 2003)  and humans of a range of HLA haplotypes (Valle et al. 2001). 
Thus, immunisation with Ag85B100-118 may potentially induce a protective response 
against Mtb. 
Here, we investigate how attachment of the RGD motif to Ag85B100-118 influences 
DC uptake, peptide presentation and processing, production of a Th1 polarising cytokine 
(IL-12) and DC migration. We asked whether the RGD-peptide was superior to the 
unmodified peptide in these properties, which would then favour the use of the 
RGD-peptide in a subunit tuberculosis vaccine.  
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3.3 Materials and Methods 
 
3.3.1 Peptide synthesis and preparation 
 
The two purified peptides used in this study, Ag85B100-118 
(FLTSELPQWLSANRAVKPT) and RGD-Ag85B100-118 
(RGDFLTSELPQWLSANRAVKPT), were custom synthesised by Invitrogen, with or 
without either fluorescein (FITC) or BODIPY conjugation. They were reconstituted in 
sterile endotoxin-free water.  
 
3.3.2 Generation of dendritic cells from proliferating mouse bone marrow progenitors 
 
Bone marrow was obtained from femurs of Balb/c mice by flushing the shafts 
with sterile Dulbecco's Modified Eagle's Medium containing 20% foetal calf serum 
(DMEM-20). Clumps of cells were broken up before seeding in 5 ml of DMEM-20 
containing 20 ng/ml GM-CSF (R&D Systems) in a 35 mm petri dish for overnight 
culture. Non-adherent cells were transferred to a new dish after 24 h without changing of 
culture media. Subsequently, cells were washed and fed every two days with fresh 
DMEM-10 containing 10 ng/ml GM-CSF. By day 6, >70% of bone marrow progenitors 
had differentiated to immature DCs, based on flow cytometric assessment of the 
proportion of CD11c+ cells. These were called bone marrow-derived DCs (BMDCs). 
 
3.3.3 Flow cytometry  
 
Cells were washed three times by centrifugation at 600 × g for 5 min before 
resuspension in 50 µl of PBS containing 0.5% bovine serum albumin (BSA). Cells were 
stained with the appropriate antibodies for 30 min at 4 °C in the dark. The respective 
isotype controls were used to determine background staining. After incubation, cells were 
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washed with 1 ml of PBS containing 0.5% BSA before resuspension in 50 µl of 2% 
paraformaldehyde for fixation. Cells were filtered to remove clumps before performing 
flow cytometry (FC500, Beckman-Coulter).   
 
3.3.4 In vitro antigen uptake assay 
 
Day 6 BMDCs were washed once, centrifuged at 600 × g for 5 min, then 
incubated with 20 µM of fluorescent peptide in DMEM-10 for 2 h. To account for 
non-specific binding of fluorescent peptides to the DC surfaces, control tubes were 
incubated with peptides for 2 h on ice, which largely prevents active peptide uptake. DCs 
were washed before staining with anti-CD11c antibody for flow cytometry to determine 
the percentage of DCs which had taken up the peptide.  In a second experiment, following 
peptide uptake, CD11c+ DCs were stained with labelled antibodies against CD51, CD61, 
CD29 and CD49 to determine the expression of integrins on DCs which had taken up 
fluorescent peptide. All antibodies were from BioLegend. 
 
3.3.5 Generation of splenic responder T cells 
 
6-8 week old specific pathogen free (SPF) Balb/c mice were either untreated 
(naïve) or injected intraperitoneally with 106 colony-forming units of live bacteria 
Mycobacterium bovis bacille Calmette-Guérin (BCG-immunised). One week later, mice 
were sacrificed to obtain splenic single cell suspensions. After brief lysis of splenic red 
blood cells in ammonium chloride and magnetic depletion of B cells using CD19-
Dynabeads (Dynal Biotech), the remaining splenocytes were cultured overnight and non-
adherent cells harvested to obtain a T cell-enriched preparation.  
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3.3.6 Antigen and processing pathway 
 
Day 6 BMDCs were seeded at 2 × 105 cells in 200 µl DMEM-10 in 96 well round-
bottom cell culture plates. MHC class I or MHC class II pathway inhibitors (0.3 mM 
monensin and 0.2mM phenylmethanesulphonylfluoride respectively) were added for 2 h 
before adding 50 µg/ml of FITC-conjugated peptides for 4 h to the cells, without 
removing the inhibitors. Subsequently, wells were washed twice with 200 µl DMEM and 
cells fixed with 2% paraformaldehyde for 10 min. Finally, the wells were washed once 
with 120 µl of 0.5 M DL-lysine (Sigma) to inactivate the paraformaldehyde, and 
subsequently washed four times with 200 µl DMEM. Responder T cells from BCG-
immunised mice were then added at a density of 5 × 105 cells in 200 µl DMEM-10 for 
24 h incubation before supernatants were harvested for measurement of IL-2 levels using 
the Mouse IL-2 ELISA MAX Deluxe kit (BioLegend). 
 
3.3.7 Production of IL-12(p70) 
 
Day 6 BMDCs were seeded at a density of 5 × 104 in 100 µl of RPMI 1640 
supplemented with 5% FCS (RPMI-5) in 96 well plates.  Peptides at 100 µg/ml or PBS 
(negative control) were added for 24 h. Supernatants were removed and wells washed 
with 200 µl of RPMI-5 to remove excess peptide. Responder T cells from naïve mice 
were added, at a density of 5 × 105 in 200 µl of RPMI-5 per well, to the peptide-pulsed 
DCs. The plate was centrifuged at 250 × g for 4 min, before incubation for 48 h at 37 ºC 
in a humidified 5% CO2 incubator. In separate wells, PBS-treated DCs alone and naïve T 
cells alone were cultured as negative controls. Supernatants were harvested for 
measurement of IL-12 (p70) levels using the OptEIA mouse IL-12 (p70) ELISA kit (BD 
Pharmingen). 
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3.3.8 Apoptosis assay 
 
Day 6 BMDCs were seeded at a density of 5 × 104 in 100 µl of RPMI-5 in 96 well 
plates.  Peptides at 100 µg/ml or PBS (negative control) were added for 24 h. DCs were 
stained with labelled anti-CD11c-PE (Biolegend), Annexin V (BD Pharmingen) and 
7-Amino-Actinomycin D (7AAD) (BD Pharmingen). Flow cytometry gated on CD11c+ 
cells was performed to determine the percentage of apoptotic DCs, defined as Annexin V+ 
and 7AAD- cells. 
 
3.3.9 Chemotaxis assay 
 
Day 6 BMDCs were resuspended in DMEM-10 and incubated with peptides at 
100 µg/ml for 8 h, then the cells were washed.  DCs (2 × 105) were added to the upper 
chambers of a transwell tissue culture plate of pore size 5.0 µm (Costar) in 6 replicate 
wells. Lower chambers contained 600 µl of DMEM-10 with or without 100 ng/ml of CC 
chemokine ligand-19 (CCL-19) (PeproTech). Transwell plates were incubated at 37 °C in 
a humidified 5 % CO2 incubator for 90 min. Cells were then collected from the lower 
chamber, fixed and stained with anti-CD11c as previously described. By flow cytometry, 
the absolute number of CD11c+ cells was obtained by comparison with FlowCount 
spheres (Beckman), according to manufacturers instructions.  Chemotaxis index (CI) was 
calculated as the ratio of number of migrated cells in response to CCL-19, to the number 
of cells which migrated spontaneously (in wells without CCL-19). In our optimization for 
this experiment, we investigated 3 different CCL19 concentrations, 1 ng/ml, 10 ng/ml and 
100 ng/ml and the chemotactic index (using PBS, Ag85B and Ag85BRGD) was 





At least three replicate wells were analysed for each treatment condition. An 
unpaired, two-tailed Student t test was used to determine whether results were 
significantly different between wells with different treatments. Results were considered 






3.4.1 Generation of dendritic cells from bone marrow progenitors 
 
To verify the efficacy of BMDC generation, flow cytometry was performed on 
day 0 and day 6 bone marrow cell cultures. Flow cytometric analysis revealed that by day 
6, at least 70% of mouse bone marrow progenitors had differentiated to DCs (defined as 
CD11c+ cells) (Fig. 3-1). At day 6, the markers expressed on the cells are typical of 




Fig 3-1: Generation of DCs from bone marrow progenitors using GM-CSF. Flow 
cytometery was used to determine the percentage of DCs obtained at day 0 and day 6 of 
culture. Thin line depicts cells stained with isotype control antibody. Heavy line depicts 
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3.4.2 In vitro antigen uptake assay 
 
We first investigated whether peptide uptake by BMDCs was influenced by the 
presence of the RGD motif in the peptide. DCs were incubated with either of the two 
fluorescent peptides (Ag85B-FITC or RGDAg85B-FITC) for 2 h and CD11c+FITC+ 
double-positive cells were identified by flow cytometry. In order to distinguish between 
the antigen molecules that are bound to the cell surface from the antigen molecules that 
have been internalised by the DCs, control tubes containing DCs incubated with RGD-
Ag85B100-118 and unmodified Ag85B100-118 were placed on ice. In such control tubes, the 
antigen molecules are still randomly (passively) bound to the cell surface, but are not 
taken up actively. Thus, the background surface binding was accounted for, and shown 
to be less than the active uptake (Fig. 3-2). A greater number of DCs taking up the 
RGD-Ag85B than the Ag85B peptide was consistently observed over ten independent 
experiments using different sets of BMDCs (Fig. 3-2). Thus, the RGD motif had a small 





We next investigated whether the presence of the RGD motif in the peptide led to 
preferential uptake by BMDCs expressing integrins α5β1 and αvβ3. In day 6 BMDC 
cultures, by flow cytometry, we found that 52% and 63% of CD11c+ cells expressed the 
α5β1 and αvβ3 integrins respectively (data not shown). We used BODIPY-conjugated 
peptides to observe DC uptake. In DCs that expressed either α5β1 or αvβ3 integrins, there 
was an approximately 2-fold greater proportion of cells that took up RGD-peptide than 
control Ag85B peptide (Fig.3-3); this difference was statistically significant.  In contrast, 
in DCs that did not express αvβ3 integrins, there was no significant difference in the 
uptake of unmodified and RGD-peptides. Although in DCs that did not express α5β1 
integrins, there was a significant difference in the uptake of unmodified and RGD-
peptides, the magnitude of difference was negligible (1% and 2.8% respectively). Since 
the attachment of the RGD motif to the Ag85B peptide preferentially improves DC 



























g85B R - g85B Ice 
Figure 3-2: Antigen uptake by 
GM-CSF differentiated DCs. Day 6 
BMDCs were incubated with 
fluorescent peptides for 2 h. To 
control for non-specific uptake of 
peptides by DCs, control tubes were 
incubated with the same peptides on 
ice. Flow cytometry was performed to 
determine numbers of peptide-
positive CD11c+ cells. Triplicate 
results from one representative 
experimental data set out of 10 
independent experiments are shown, 
error bars represent 1 S.D. 
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positive cells, this supports the likelihood that, especially for αvβ3 integrin-positive cells, 











Figure 3-3: Antigen uptake by GM-CSF differentiated DCs expressing integrins 
CD51/61 (αvβ3+) or CD29/49 (α5β1+). Day 6 BMDCs were incubated with either 
fluorescent Ag85B or RGD-Ag85B peptides for 2 h then stained with anti-CD11c and 
either anti-CD51/61 (A and C) or anti-CD29/49 (B and D). Expression of the respective 
markers indicated (A  D) was used to define different cell types. Histograms gated on 
the respective cell types show the extent to which each cell type was peptide-positive. 
Dotted line: isotype antibody stained. Gray line: Ag85B peptide. Black line: 
RGD-Ag85B.  E  F: Bar charts show quantitative data from replicate experiments 




























































































pertaining to CD51/61(αvβ3)-positive and -negative cells (E) and CD29/49 (α5β1)-positive 
and -negative cells (F), error bars represent 1 S.D.  
3.4.3 IL-2 production and antigen processing and presentation pathway 
 
Ag85B is known to be expressed by live BCG in the host (Harth et al. 1996). T 
cells from BCG-immunised mice were co-cultured with the peptide-pulsed BMDCs and 
IL-2 production measured as an indicator of T cell response following antigen 
presentation. There was significantly more IL-2 produced by T cells co-cultured with 
DCs pulsed with RGD-Ag85B than Ag85B (Fig. 3-4A). Thus, presentation of the 
RGD-peptide was more effective in stimulating a recall T cell response. Although studies 
have not indicated that the attachment of the RGD motif,  we wanted to verify this by 
investigating whether the MHCI or MHCII pathway is more important to the processing 
and presentation of the DC peptide, MHC class I or II inhibitors were added to the DCs 
prior to pulsing with either of the two peptides. 
Both pathway inhibitors blocked the presentation of the peptides to the responder 
T cells significantly, with a relatively greater effect on RGDAg85B-pulsed than Ag85-
pulsed cells, particularly with respect to class II inhibition (Fig. 3-4B). IL-2 levels elicited 
from the responder T cells upon co-culture with Ag85-pulsed DCs declined by 33% and 
38% respectively in the presence of class I and II inhibitors. The decrease was 40% and 
50% respectively with RGDAg85B-pulsed DCs. Hence, presentation of the RGD-peptide 
was relatively more Class II dependent than Class I dependent. When the Ag85B peptide 
was subjected to in silico analysis using the software PREDBALB/c (Zhang et al. 2005) for 
epitope-binding prediction, the result suggested that the Ag85B peptide sequence 
contained several high-binding Class II epitopes but no strong class I - binding epitopes 
(Tables 3-1 and 3-2).  
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Figure 3-4: IL-2 production upon peptide presentation to T cells. A: Day 6 GM-CSF 
differentiated DCs were incubated with peptides or PBS for 4 h, then fixed and co-
cultured with T responder cells from BCG-immunised mice for 24 h. Supernatants were 
harvested for measuring IL-2 production.  B: MHC I or MHC II pathway inhibitors or 
PBS were added for 2 h prior to peptide incubation, and the same T cell co-culture 
experiment was performed. The percentage decrease of IL-2 following addition of 
inhibitors was based on: (difference in IL-2 produced with and without inhibitors/ IL-2 
produced in absence of inhibitors) × 100%. Results show means from 4 replicate wells, 
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Table 3-1: Prediction of MHC class II epitopes in the 19-mer Ag85B100-118 peptide using 
PREDBALB/c software. Plot prediction score reflects the binding strength of the predicted 
epitope. A score of > 8.0 indicates epitopes that bind strongly to MHC class II haplotypes 
of Balb/c mice (indicated in bold). Position numbering indicates the position of the first 



























Table 3-2: Prediction of MHC class I epitopes in the 19-mer Ag85B100-118 peptide using 
PREDBALB/c software. Based on a threshold of 8.0 in the plot prediction score, there were 
no epitopes that bound strongly to MHC class I haplotypes of Balb/c mice. Refer to Table 







3.4.4 In vitro DC production of IL-12(p70) 
 
IL-12(p70) production by DCs primes Th1 responses, which are important in 
protection against tuberculosis. Although the process of DC maturation is triggered by 
microbial products via the interaction with TLRs, interactions with various lymphocyte 
populations also modulate the priming capacity of mature DCs (Behrens et al. 2004; de 
Jong et al. 2005). Therefore in order to make the in vitro experiment as physiological as 
possible, we co-cultured peptide-pulsed BMDCs with naïve T cells (Fig. 3-5) and 
measured IL-12(p70) production. There was a 10-fold higher level of IL-12(p70) in the 
wells containing DCs pulsed with RGD-Ag85B than Ag85B. There was no detectable IL-
12(p70) production in wells without peptide, showing that the cytokine production was 
peptide-specific. Hence, the attachment of the RGD motif significantly increased the 






























Figure 3-5: IL-12(p70) DC response to 
peptide in DC-T cell co-cultures. DCs 
were pulsed with peptides or PBS and 
co-cultured with naïve T cells for 48 h
before measuring IL-12 in the 
supernatants. PBS-stimulated DCs 
(unstim DCs) and naïve T cells alone 
(unstim T cells) were cultured in 
separate wells as controls. Means of 
four replicate wells are shown, error 
bars represent 1 S.D. 
ND: Not detectable. 
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3.4.5 In vitro DC migration assay 
 
Peptide-pulsed BMDCs were allowed to migrate across a transwell membrane 
towards a lower chamber containing CCL19. Wells without the chemokine served as 
controls for spontaneous migration (Fig. 3-6). In several independent experiments, there 
was a consistent trend showing that more of the DCs pulsed with RGD-Ag85B migrated 
in response to chemokine CCL19 than Ag85-pulsed DCs. Although the differences in 
chemotactic index were not statistically significant, uptake of RGD-peptide had at least a 
small influence on DC migration.  
 
 
3.4.6 Apoptosis of DC 
 
BMDCs pulsed overnight with peptides were stained with CD11c, Annexin V and 
7AAD to determine the percentage of DCs which had undergone apoptosis. PBS-pulsed 
DCs served as the negative control. Both Ag85B and RGD-Ag85B peptide pulsed DCs 



















 Ag85 R -Ag85B
Figure 3-6: Chemotactic migration of 
peptide-pulsed DCs. Day 6 BMDCs 
were pulsed with peptides for 8 h and 
migration in response to CCL-19 
through a transwell membrane was 
measured by counting the absolute 
number of CD11c+ cells in the lower 
chamber by flow cytometry. 
Chemotactic index represents the fold 
increase in the number of migrated 
DCs in response to CCL-19, over the 
number which migrated 
spontaneously. Mean results of 3 
independent sets of experiments are 
shown, error bars represent 1 S.D. 
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(32.8%) after overnight culture. However, the RGD-Ag85B peptide-pulsed DCs did not 
show a substantial decrease in apoptosis compared to DCs pulsed with Ag85B peptide. 
Approximately 42% of the BMDCs cultured in 5% DMSO were apoptotic (Fig. 3-7).  
















































Figure 3-7: Susceptibility of peptide-pulsed DCs to apoptosis. Day 6 BMDCs were 
pulsed with PBS or peptides overnight then stained with CD11c, Annexin V and 
7AAD. Flow cytometery was performed, gated on CD11c+ cells to determine the 
percentage of apoptotic DCs. Apoptotic cells were defined as  
Annexin V+7AAD- cells. Results shown represent 2 experiments with similar results, 




Tuberculosis is still of global concern although the BCG vaccine has been widely 
available for many decades (Kaufmann et al. 2006). The failure of BCG in controlling 
adult TB appears to be due to a lack of long-lasting T cell memory. Although various 
studies have indicated that it provides effective protection against severe forms of 
childhood TB, such as meningitis and disseminated miliary TB (Awasthi et al. 1999), its 
efficacy in protection against adult pulmonary TB is variable, from 80% to nil (Colditz et 
al. 1994).  In the search for improved TB vaccines, vaccinologists have begun to explore 
DC manipulation strategies, in a bid to generate potent, long-lasting T cell memory.  
Attempts have already been made to utilise ex vivo DCs pulsed with Ag85 antigens in 
murine vaccine studies.  When Ag85A from Mtb was used to pulse DCs which were then 
delivered intranasally to mice, an increase in the numbers of IFN-γ-secreting CD4+ and 
CD8+ T-cells in the lung were observed, but without increased  protection against 
pulmonary Mtb challenge (Gonzalez-Juarrero et al. 2002). DCs transduced with 
adenoviral vector expressing Ag85A and introduced intramuscularly were more 
successful than Ag85A peptide or protein-pulsed DCs in eliciting a sustained cytotoxic T 
cell response and conferring protection against challenge (Malowany et al. 2006). 
However, ex vivo DC manipulation and re-introduction into the host is not widely 
applicable for a mass vaccination strategy. 
The peptide vaccine approach is ideal with respect to costs, stability, 
reproducibility and safety. The disadvantages are that specific epitope recognition by 
certain HLA haplotypes may be limited, and immunogenicity is often weak, in part due to 
low numbers of DCs at the injection site for uptake of the antigen and also because 
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peptides do not contain a danger signal  (Matzinger 2002).  To address these factors, we 
chose an immunodominant peptide of Ag85B which is promiscuously recognised by 
patients of a range of HLA haplotypes (as well as Balb/c mice). Additionally, we sought 
to improve the targeting of the peptide to integrin-expressing antigen-presenting cells by 
incorporating the RGD motif into the N-terminus of the peptide. In this present study, we 
were interested in understanding how taking up the RGD-linked peptide, as opposed to 
the unmodified peptide, could change the behaviour and response of DCs.  
There was a small but consistently reproducible increase in the in vitro uptake of 
RGD-Ag85B100-118 relative to unmodified Ag85B100-118 (Fig. 3-2). This indicates that the 
addition of the RGD motif increases peptide uptake by DCs, and we believe this relates to 
improved peptide recognition. Immature DCs are specialised in a variety of endocytic 
uptake mechanisms. Receptors on the plasma membrane capture substances or particles 
by binding to their specific ligands (Xiang et al. 2006). We found that in DCs not 
expressing the αvβ3 integrins, there was no difference in the uptake of the RGD-Ag85B 
peptide and the Ag85B peptide, while in DCs expressing the αvβ3 integrins, there was a 
greater proportion that took up RGD-Ag85B peptide than control Ag85B peptide. This 
suggests that in the presence of the αvβ3 integrins, the attachment of the RGD motif to the 
Ag85B peptide increases targeting to DCs with associated better uptake. This is in 
agreement with studies showing that the RGD binds integrins such as α1β1, α2β1, α5β1, 
αvβ1 and αvβ3 (Ruoslahti et al. 1987). A study using a modified adenovirus vector 
expressing RGD in the capsid has also shown that infection (transduction) is dependent 
on the expression of CD51 (αv) (Harui et al. 2006). Internalisation of human adenovirus 
into host cells is dependent on its penton base containing five RGD sequences (Bai et al. 
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1993; Wickham et al. 1993), which bind to the host cell receptors αvβ3 and αvβ5. This 
allows virus internalisation via clathrin-coated vesicles by receptor-mediated endocytosis 
(Chardonnet et al. 1970; Varga et al. 1991).  A similar mechanism could allow RGD-
peptides to be internalised by DCs. Although peptides without the RGD motif could be 
taken up by fluid-phase endocytosis via micropinocytosis and/or macropinocytosis 
(Swanson et al. 1995; Amyere et al. 2002), the integrin-mediated uptake provides an 
additional means for uptake of the RGD-peptide which is likely to be more efficient.  
The ability of DCs to take up and present antigen to antigen-specific T cells, with 
subsequent generation of memory T cells is important. However, the nature of the DC 
signal is also crucial in determining the type of T cell response induced (Macagno et al. 
2007). DC production of IL-12 is known to promote IFN-γ production and Th1 responses 
that are crucial for macrophage activation; thus IL-12 is essential for the induction of 
anti-mycobacterial immunity. Genetic defects in either IFN-γ or IL-12 pathways are 
associated with susceptibility to Mycobacterium infections in humans and mice (Cooper 
et al. 1993; de Jong et al. 1998). The early administration of IL-12(p70) to Mtb-infected 
Balb/c mice results in significantly decreased bacterial burdens, increased survival time 
(Flynn et al. 1995) and reduced pathology (Nolt et al. 2004), while neutralisation of 
IL-12(p70) at the initiation of Mtb infection leads to increased bacterial loads and reduced 
integrity of granulomas (Cooper et al. 1995). This may relate to the role of IL-12 in DC 
migration from the lung to the draining nodes in Mtb infection (Khader et al. 2006). It 
was thus reassuring to note that our RGD-peptide was significantly better than the 
unmodified peptide in inducing IL-12(p70) responses in the pulsed DC-T cell co-culture 
experiment (Fig. 3-5). Interaction of the RGD motif and αv integrin induces the activation 
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of phosphotidylinositol 3 kinase (PI3K) (Li et al. 1998; Nemerow 2000), which mediates 
NF-κB induction and drives secretion of cytokines by DCs (Philpott et al. 2004). This 
could explain why the RGD-peptide induces more IL-12 production than the control 
peptide. Our observations are consistent with data based on an RGD fiber mutant of the 
adenovirus (AdRGD) which targets αv integrin, showing that protein expression levels of 
IL-12(p40), TNF-α and IFN-α in DCs increased with time after treatment with AdRGD 
(Kanagawa et al. 2008).  
The MHC epitope prediction (Tables 3-1 and 3-2) and prior Balb/c epitope 
mapping studies (D'Souza et al. 2003) suggest that Ag85B100-118 is a strong MHC II 
epitope (but a weak MHC I epitope), thus it was not surprising that recognition of both 
RGD-Ag85B100-118 and Ag85B100-118 was more affected by Class II than Class I inhibitors 
(Fig. 3-4B). Since Class I, and particularly Class II, inhibition had a significantly greater 
impact on the response to RGD-peptide than unmodified peptide, it is probable that the 
RGD motif influences the processing of the Ag85B peptide in the DCs. Separately, we 
also showed that presentation of the RGD-peptide was able to stimulate a higher level of 
IL-2 response from T cells of BCG-immunised mice than peptide alone (Fig. 3-4A); thus 
T cell responses to RGD-peptide presentation also led to higher levels of T cell activation 
in a recall (memory) response. This would argue in favour of using the RGD-peptide as a 
booster vaccine in a prime-boost schedule, with BCG priming given in early childhood, 
as is currently practiced in many countries. 
After immature DCs in the peripheral tissues take up antigens, en route to the 
lymph nodes, they transform into mature DCs which have reduced capacity for antigen 
uptake but significantly improved T cell stimulatory capacity (Mellman et al. 2001). 
  48
CCL-19 is expressed in the T cell area of lymph nodes, thus inducing the migration of 
mature DCs. During mycobacterium infection, the sustained expression of CCL19 in the 
lung results in the recruitment and retention of DCs that can activate naïve CD4 T cells 
in situ (Anis et al. 2008). We found that the DCs pulsed with RGD-peptide showed 
increased chemotaxis in vitro in response to CCL-19, relative to the Ag85B peptide 
(Fig. 3-6). Molecular mechanisms regulating DC trafficking have not been fully 
elucidated. It has been shown that treatment of skin explants with a GRGDS pentapeptide 
to block α5β1 integrin-fibronectin interactions does not affect Langerhans cells migration 
(Price et al. 1997). However, more recently, it has been noted that integrin-linked kinase 
(ILK) disruption in lymphocytes results in reduced migratory response to CCL-19. Since 
ILK is required for inside-out activation of α5β1 (Camacho-Leal et al. 2007), if a similar 
mechanism occurs in DCs, this could explain how integrin activation via RGD binding 
may increase the chemotactic response to CCL-19.   
It has also been suggested that besides facilitating attachment to proteins of the 
extracellular matrix, integrin-mediated signalling can also affect cell behaviour. For 
example, cell attachment via RGD-containing ECM proteins to α5β1 and αvβ3 integrins 
has been shown to promote cell survival by upregulation of Bcl-2 (Zhang et al. 1995; 
Matter et al. 2001). Mutant melanoma cells which lack the integrin gene (αv gene), 
therefore lacking an intact integrin receptor, are susceptible to apoptosis, reversible upon 
transfection with the αv gene (Mason et al. 1996). Therefore, we postulated that uptake of 
RGD-peptide may act via integrin signalling to reduce the susceptibility of the DCs to 
apoptosis, thus allowing them to be more effective in stimulating protective T cell 
responses. However, DCs pulsed with RGD-Ag85B or unmodified peptide did not show 
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differential apoptosis (Fig. 3-7). This may be because the binding of the RGD-peptide to 
the integrin receptors on DCs was not sufficiently strong, or because the peptide uptake 
via RGD-integrin binding was not extensive enough to trigger this effect. 
Overall, our in vitro observations suggest that the addition of the RGD motif to 
Ag85B peptide increased its uptake by DCs, at least in part through integrin-mediated 
endocytosis, with associated increases in DC migration, IL-12 production, and induction 
of a recall response in co-cultured T cells. We acknowledge that we have not sought to 
demonstrate the precise mechanism by which RGD-peptide achieves these downstream 
immunological effects. It is possible that the only action of the RGD-motif is to increase 
the uptake of the Ag85B peptide by the DCs (possibly by DC targeting through integrins). 
This alone could lead to more antigen presentation which consequently leads to better re-
stimulation of the T cells.  However, this final outcome of T cell activation is effectively 
the downstream immune effect that is desired of a tuberculosis vaccine. Therefore, 
whether it is an indirect consequence of better antigen-delivery to DCs, or a direct effect 
of RGD-peptides, was not a focus of our research. In particular, improving delivery to 
DCs is important as this is a major source of poor immunogenicity often associated with 
with peptides as vaccines.  In the next chapter of this thesis, the in vivo immune responses 
to RGD-Ag85B100-118 versus Ag85B100-118 are compared in Balb/c mice and those results 
show significant improvements in host response attributable to RGD-peptide. The 
simplicity of the method for achieving these immunological enhancements holds promise 
for its general usage in the design of subunit vaccines.  
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There is a need for a new tuberculosis vaccine which can overcome the safety 
concerns and lack of efficacy of the current vaccine Mycobacterium bovis bacille 
Calmette-Guérin (BCG) in adult populations with pre-exposure to environmental 
mycobacteria. A subunit vaccine approach, based on the immunogenic tuberculosis 
antigen, Ag85, is considered here. We previously showed that a novel dendritic cell (DC) 
integrin receptor targeting strategy involving the use of the RGD motif conjugated to an 
Ag85B peptide leads to this peptide being preferentially taken up by DCs, relative to 
unmodified peptide.  In this present study, expansion of DCs in lungs and spleens of mice 
was achieved by administration of two doses of fms-like tyrosine kinase ligand (Flt3L). 
This was followed by three subcutaneous doses of the RGD-tagged peptide 
(RGD-Ag85B) vaccine in a Th1-inducing adjuvant, TDB/DDA (trehalose 6, 6'-
dibehenate/ dimethyl dioctadecyl ammonium bromide), and the host cellular response 
was compared with mice given unmodified peptide in the same vaccination strategy. 
Although less immunogenic than whole live BCG, the RGD-peptide elicited a relatively 
higher level of T cell proliferation,  Th1 cytokine induction, generation of IFN-γ 
producing epitope-specific T cells and an increase in CD4 and CD8 T cell proportions 
compared to unmodified Ag85B peptide-immunised or naïve mice. These results prove, 
in principle, that the RGD-peptide vaccine approach, combined with Flt3L for DC 
expansion, is a promising method for enhancing immunogenicity and host cellular 




The current tuberculosis (TB) vaccine, bacille Calmette-Guérin (BCG) is an 
attenuated strain of Mycobacterium bovis with variable protective efficacy (Colditz et al. 
1994; Girard et al. 2005). Although effective in protecting infants against disseminated 
forms of TB, immunity declines with age. Many clinical trials have shown little 
protection against adult pulmonary disease (Fine 1989; Rodrigues et al. 1993; Colditz et 
al. 1994). Suboptimal responses to BCG could be related to prior immune priming by 
environmental mycobacteria (Palmer et al. 1966; Fine 1995). Other considerations also 
limit usage of BCG. For example, as a live vaccine, BCG is unsuitable for 
immunocompromised patients. BCG vaccination also leads to tuberculin reactivity, thus 
reducing the value of this test in diagnosis of infection (Kearns et al. 1985). There are 
now more specific diagnostic tests for latent infection such as Quantiferon (Gerald H. 
Mazurek 2003). Additionally, BCG cannot be used as a post-exposure vaccine to prevent 
reactivation of latent infection or as immunotherapy for those with early infection (ten 
Dam et al. 1982). There is therefore much interest in subunit vaccines as new TB 
vaccines, but the design of these has to meet not only criteria of safety. They should also 
induce long-lived immunity, be usable after exposure to mycobacteria and should 
preferably not compromise our current methods for TB diagnosis.  
Dendritic cells (DCs) play a major role in the cellular response to TB. In M. 
tuberculosis (Mtb) murine aerosol challenge, DCs, and not macrophages, which have 
been infected with Mtb or have taken up Mtb antigens, initiate primary Th1 responses at 
draining lymph nodes (Bhatt et al. 2004), and secrete IL-12 (Giacomini et al. 2001; 
Hickman et al. 2002). Apoptotic vesicles from infected cells transport mycobacterium 
antigens to DCs, allowing cross-priming of CD8 cells, which are important against this 
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intracellular bacterium (Winau et al. 2006). Thus, a successful TB subunit vaccine needs 
to invoke good DC recognition and presentation of the vaccine antigen. 
Immunodominant proteins found in both Mtb and BCG can be useful for both 
primary and post-BCG booster vaccines. Ag85B a mycolyl-transferase required for Mtb 
cell wall biogenesis (Belisle et al. 1997) has gained much interest as a vaccine candidate. 
Murine vaccination studies, using either a DNA plasmid encoding Ag85B (Kamath et al. 
1999) or recombinant BCG strains overexpressing Ag85B (Horwitz et al. 2000) have 
demonstrated better protective efficacy against Mtb challenge than BCG. Vaccine studies 
in murine hosts using subunit vaccines based on Ag85B such as recombinant fusion 
proteins Ag85B-ESAT6 (Weinrich Olsen et al. 2001) and Ag85B-TB10.4 (Dietrich et al. 
2005) have been encouraging. Epitope mapping studies have identified numerous murine 
and human T cell epitopes in Ag85B (Mustafa et al. 2000; D'Souza et al. 2003). One of 
the immunogenic epitopes identified is Ag85B100-118, it is promiscuously recognised by 
major histocompatibility complex Class II of Balb/c mice (D'Souza et al. 2003)  and 
humans of a range of MHC haplotypes (Valle et al. 2001). We therefore chose the peptide 
Ag85B100-118 as a subunit vaccine for our present study in Balb/c mice.  
Relative to whole bacteria or recombinant proteins, peptide vaccines usually have 
weak immunogenicity (Gonzalez-Juarrero et al. 2002).  To overcome this, our strategy 
was to induce in vivo DC expansion using Fms-like tyrosine kinase ligand (Flt3L) and 
then to introduce DC-targeted peptides subcutaneously, in the presence of a Th1-inducing 
adjuvant. For DC targeting, we linked the Ag85B peptide to an integrin-binding motif 
arginine-glycine-aspartic acid (RGD). In the previous chapter, it was demonstrated that a 
larger proportion of DCs expressing integrins α5β1 and αvβ3 took up this RGD-peptide 
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than the unmodified equivalent peptide,  in agreement with other studies showing that the 
RGD motif targets DCs via these integrins (Harui et al. 2006). RGD at the N-terminus of 
a peptide vaccine has been shown to increase its immunogenicity, and may have an 
adjuvant-like effect (Yano et al. 2003; Yano et al. 2005). To augment the DC response, 
we administered Flt3L prior to vaccination, as this expands both conventional DCs and 
plasmacytoid DCs in vivo (McKenna 2001). In human and murine vaccine studies 
(Maraskovsky et al. 2000; Pisarev et al. 2000), Flt3L increases the DC population in 
tissues, with associated enhancements in immune responses against soluble protein 
antigens. In particular, expansion of the CD8α+, CD8α-CD4+ and CD8α-CD4- DCs, 
dermal DCs in the lymph nodes and pDC precursors, but not Langerhans cell DCs, has 
been observed (Sheu et al. 1997).  The CD8α+ and CD8α- DC subsets can prime antigen-
specific CD4+ and CD8+ T cells efficiently and induce secretion of IL-12 in vitro (Villard 
et al. 2006). For the adjuvant, we used trehalose 6, 6'-dibehenate/ dimethyl dioctadecyl 
ammonium bromide (TDB/DDA). TDB is a synthetic analogue of trehalose 6, 6-
dimycolate (TDM), an immunostimulatory component of the mycobacterial cell wall. 
TDB increases the stability and adjuvant efficacy of DDA liposomes (Davidsen et al. 
2005). DDA, a cationic, micelle-forming surfactant with a weak Th1-stimulating effect, 
promotes protective immunity when used alone or in combination with TDB as an 
adjuvant for TB subunit vaccines in murine studies (Stanfield et al. 1973; Lindblad et al. 
1997; Brandt et al. 2000; Holten-Andersen et al. 2004).  A TB fusion protein in this 
adjuvant system induces strong responses from primed T cells with a Th1 bias (Davidsen 
et al. 2005) and yields protection comparable to BCG-vaccinated mice after Mtb 
challenge (Holten-Andersen et al. 2004). 
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Here, we investigate the immunological effects of the RGD-Ag85B peptide, 
relative to the unmodified peptide, when administered with TDA/DDB in a schedule that 
includes Flt3L expansion of DCs before vaccination.  
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4.3 Materials and Methods 
 
4.3.1 Peptide synthesis and preparation 
 
The two purified peptides used in this study were chemically synthesised by 
Invitrogen. They were reconstituted in sterile endotoxin-free nanopure water and stored at 
-80°C before use.  The single-letter universally accepted notation for amino acids is used 






Mycobacterium bovis bacille Calmette-Guérin (BCG) Pasteur strain was grown on 
Middlebrook 7H10 agar or 7H9 broth (Difco), supplemented with oleic acid-albumin-
dextrose-catalase (OADC, Difco) and 0.1% Tween 20. Broth cultures were always used 
at mid-log phase, bacteria counts in broths were estimated by spectrophotometric 
absorbance at 600 nm and subsequently enumerated by colony-counting in serial dilutions 
on agar. BCG from broth cultures were washed twice with PBS and resuspended in PBS 
before the suspension was passed through a 21G needle to reduce bacteria clumping 






4.3.3 Murine immunisation and tissue processing 
 
6- to 8-week old pathogen-free female Balb/c mice were used, with protocols 
approved by the institutional animal care and use committee. Murine Flt3L (Appendix 7.1 
and 7.2) immunisations were delivered intra-peritoneally, whereas peptide antigen, PBS 
or live BCG (5 × 105) were given subcutaneously in the scruff of the neck together with 
the adjuvant (Appendix 7.3). DDA (Sigma) and TDB (Avanti Polar Lipids) (Holten-
Andersen et al. 2004) were, respectively, used at 250 µg and 300 µg per dose and were 
continuously mixed with 200 µg of antigen for 30 min at room temperature before 
immunisation.  
Spleens were digested in 18.5 pzu/ml collagenase D (Serva) for 1 h and passed 
through a 70 µm nylon cell strainer to obtain single cell suspensions. After red cell lysis, 
splenocytes were subjected to B cell depletion using magnetic beads (mouse pan B 
(B220) Dynabeads, Invitrogen) before use.  
Lymph nodes were homogenised through the cell strainer to obtain single cell 
suspensions, which were washed twice in 5 ml of RMPI-1640 supplemented with 5% 
FCS (RPMI-5) before use. In experiments which examined the DC proportion in lymph 
nodes, prior to homogenisation, lymph nodes were digested in collagenase D as described 
above. 
 
4.3.4 Cytokine production by immune cells 
 
For cytokine measurement, 5 × 105 cells were seeded in 200 µl of RPMI-5 per 
well in 96-well round bottom tissue culture plates. Cells were stimulated with either 
LEAF purified anti-CD3 (5µg/ml) and anti-CD28 (2µg/ml) (BioLegend) or 100 µg/ml of 
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Ag85B100-118 for 48 h at 37 °C in a humidified 5% CO2 incubator before collection of 
supernatants for ELISA, performed with ELISA MAX Set (IL-2, BioLegend) or OptEIA 
mouse ELISA kits (IFN-γ and IL-12p70, BD Pharmingen).  
 
4.3.5 Ag85B epitope-specific IFN-γ ELISPOT assay 
 
Assay was performed according to ELISPOT kit instructions (mouse IFN-γ 
ELISPOT set, BD Pharmingen). Briefly, cells were seeded in a Multiscreen HTS 96 
well filter plate (Milipore) coated overnight with IFN-γ capture antibody (5µg/ml), 
at a density of 5 × 105 cells in 200 µl of RPMI-5.  After 24 h stimulation with 100 
µg/ml of Ag85B100-118, wells were washed with deionised water before adding 
detection antibody and streptavidin-horse radish peroxidase conjugate for 1 h. 
Colour development was performed with 3-amino-9-ethyl-carbazole substrate for 
40 min. Plates were then air-dried and read with an ELISPOT reader (Bioreader 
4000, Biosys). Control wells without any cells or with PBS-stimulated cells were 
included.  
 
4.3.6 Proliferation assay 
 
Cells were seeded at 5 × 105 cells in 200 µl of RPMI-5 containing 10% (vol/vol) 
AlamarBlue dye (Biosource) and immediately stimulated with 100 µg/ml of Ag85B100-118. 
After 48 h, plates were analysed using a plate reader (Tecan Sunrise, Magellan) for 
absorbance readings at 570nm and 600nm. The percentage of reduced AlamarBlue is 
proportional to the number of proliferating cells in the culture (Ahmed et al. 1994). 
Phytohaemagglutinin (PHA) pulsed cells were used as a positive control and cells pulsed 
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with PBS were used to determine the basal level of proliferation. Wells without cells but 
containing only medium with AlamarBlue were used as additional negative controls.  
 
4.3.7 Mycobacterium killing assay 
 
Peritoneal macrophages were washed and seeded at 1 × 105 in 100 µl of RPMI-5 
containing  50 µg/ml of ferric ammonium citrate (FAC) (complete medium) before 
infection at a ratio of 10 BCG: 1 macrophage for 4 h. Extracellular BCG was removed by 
washing each well twice with 200 µl of complete medium. RBC lysed and B cell cell 
depleted splenocytes stimulated ex vivo with anti-CD3 (5 µg/ml) and anti-CD28 (2 µg/ml) 
or 100 µg/ml of Ag85B100-118 for 48 h were added at a ratio of 10 lymphocytes: 
1 macrophage in fresh RPMI-5 for 24 h co-culture in the absence of antigen. 
Subsequently, non-adherent cells were removed and macrophages lysed with 100 µl of 
0.1% saponin to harvest the intracellular BCG. The bacterial pellet was washed thrice 
with sterile PBS, and several dilutions cultured on agar in triplicates for colony 
enumeration. Control wells without T cells were used to determine the basal level of BCG 
killing by macrophages alone. Co-cultures of infected macrophages with PBS-stimulated 
T cells were used to determine the effect of antigen-specific T cells.  
 
4.3.8 Flow cytometry  
 
Cells were washed thrice by centrifuging at 600 × g for 5 min before resuspension 
in 50 µl of PBS containing 0.5% BSA (bovine serum albumin). Cells were stained with 
the appropriate antibodies (Biolegend) or their respective isotypes for 30 min at 4 °C in 
the dark. Cells were then washed with 1 ml of PBS containing 0.5% BSA, before 
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resuspension in 50 µl of 2% paraformaldehyde for fixation.  Cells were filtered to remove 
clumps before performing flow cytometry (FC500, Beckman-Coulter).   
 
4.3.9 Red blood cell lysis  
 
Lysis of red blood cells in splenocytes was performed before all assays. Cells 
were centrifuged at 350 × g for 10 min and supernatants discarded before 0.17 M 
ammonium chloride was added for 45 sec. Subsequently, 5 ml of RPMI-5 was added to 
stop the reaction.  
 
4.3.10 Trypan blue exclusion assay  
 
This assay distinguishes between viable and non-viable cells. Non-viable cells are 
stained blue. Cells were resuspended and mixed 1:1 (vol/vol) with 0.4% Trypan blue dye 
(Sigma) at room temperature for 1 min. Subsequently, 10 µl of the mixture was loaded 




All assays were performed in at least triplicate wells for each experimental 
condition, and for all data shown, at least two independent sets were performed with 
similar results. Unless otherwise stated, three mice per treatment group were studied. An 
unpaired, two-tailed Student t test was used to compare between different treatment 




4.4.1 Production of Flt3L for murine immunisation  
 
To produce Flt3L for murine immunization, CHO-K1 cells containing a plasmid 
coding for recombinant FLAG-tagged murine Flt3L were cultured and the supernatant 
was harvested for Flt3L purification using an anti-FLAG affinity column, as described in 
Appendix section 7.1. The concentration of Flt3L was estimated using the NanoDrop ND-
1000 spectrophotometer (ThermoFisher Scientific) at absorbance 280 nm. Both SDS-
PAGE gel electrophoresis with Coomassie staining (Fig. 4-1A) and Western blot 
performed with anti-FLAG antibody (Fig. 4-1B) indicated that a protein of 28 kDa was 
purified, in agreement with the estimated size of murine Flt3L protein. The level of 
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A B Fig 4-1: Production of Flt3L for 
murine immunisation. A: Purified 
Flt3L protein analysed with SDS-
PAGE gel electrophoresis and 
visualised by Coomassie staining B: 
Western blot was performed using 
anti-FLAG antibody as described in 
Appendix section 7.2. M: protein 
ladder. Lane 1: purified Flt3L. 2: 
purified Flt3L. 3: Met-FLAG-BAP, 
positive control for FLAG-tag, 
supplied by manufacturer. 4: negative 
control (cell supernatant that flowed 
through the purification column). 
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4.4.2 Optimisation of Flt3L administration schemes 
 
We first optimised the Flt3L treatment dose and frequency of Flt3L administration 
to achieve the best compromise between extent of DC expansion and minimisation of 
dosing frequency and quantity. This experiment was performed with Flt3L only, no 
antigens were given. The 4 schemes tested are illustrated (Fig. 4-2A). Daily low dose 
Flt3L (Scheme 2) gave the highest DC expansion in the spleens (41.6%), whereas the 
two-dose 75 µg Flt3L (Scheme 3) achieved the highest DC percentages in the lungs 
(22.5%) and similar levels in the spleen (26.2%). Scheme 4 achieved comparable levels 
of DC expansion as scheme 3 but required more doses of Flt3L (Fig. 4-2B). Therefore, 












Figure 4-2: Flt3L administration schemes and DC expansion. Flt3L administration 
schemes are depicted in this time-line. A: Mice were treated intraperitoneally at various 
time points (arrows) with the different doses of Flt3L (indicated in column Flt3L per 
dose) and sacrificed at different time points (). B  D: After the different Flt3L treatment 
schemes indicated, on the day of sacrifice, the percentage of DCs (CD11c+ cells) in the 
different organs were analysed by flow cytometry (ungated). In D, scheme 3 is depicted 
by the 75 µg graph and scheme 4 by the 50 µg graph.   In all cases, mice injected with 
PBS served as a control.  
 
4.4.3 Interferon-gamma production and mycobacterium killing induced by peptide 
immunisation 
 
In order to understand the immunological effects of murine immunisation with 
Ag85B or RGD-Ag85B in adjuvant formulation alone (i.e. without prior administration of 
Flt3L), mice were immunised thrice two weeks apart with peptide vaccines in adjuvant 
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(without prior Flt3L administration) and sacrificed one week after the last immunisation. 
Negative and positive control mice were immunised with PBS in adjuvant or live BCG in 
PBS, respectively. RGD-Ag85B immunised mice produced a significantly higher level of 
IFN-γ in the draining lymph nodes compared to the unmodified Ag85B-immunised mice 
(Fig. 4-3A), but the BCG-immunised mice produced the highest levels.  
Splenocytes of immunised mice were used as effector cells in co-culture with 
BCG-infected macrophages to test the functional bacterial growth limitation induced by 
immunisation (Fig. 4-3B). BCG immunisation resulted in significant reductions in 
bacteria counts compared to non-immunised (PBS control) mice. Comparing between the 
two peptide vaccines, there was no significant difference between the BCG killing 
capabilities of RGD-Ag85B and the unmodified peptide-immunised mice. BCG-
immunised mice gave the best mycobacterium inhibition. Therefore, in the absence of 
Flt3L, RGD-Ag85B immunization increases the protective response in the murine host 
relative to unmodified peptide, although this was not significantly different and neither 





 4.4.4 Optimisation of immunisation scheme 
 
In the previous experiment, we have established that it was necessary to 
administer two doses of 75 µg Flt3L peptide in order to enhance the DC numbers in vivo 
in the murine host. In this experiment, we investigated the optimal time point after Flt3L 
administration to introduce the peptide vaccine. In order to find out the optimal time point 
after Flt3L administration to introduce the peptide vaccine, and to investigate whether 
Flt3L administration had any impact on the peptide-specific Th1 response post-
immunisation, three alternative immunisation schemes were tested in three groups of 
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P=0.0423
Figure 4-3: Effect of antigen in 
adjuvant, in absence of Flt3L. Mice 
were immunised 3 times, once 
every fortnight with antigen in 
TDB/DDA adjuvant and harvested 
1 week after the last immunisation. 
Mice injected with PBS in adjuvant 
or a single dose of 5 × 105 live BCG 
served as negative and positive 
controls respectively. A: LN cells 
from pooled inguinal, brachial and 
axillary lymph nodes were 
stimulated with anti-CD3 and anti-
CD28 for 48 h before supernatants 
were collected for ELISA. B: 
Mycobacterium killing assay was 
performed using a co-culture of 
BCG-infected macrophages and 
anti-CD3/CD28 stimulated T cells 
from immunised mice, and colony 
counts (CFU) of viable BCG 
assayed by culture. Both 
experiments were performed with 
triplicates for each mice, with two 
mice for each variable. Group 
means are depicted with error bars 
showing 1 S.D.  
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mice (Fig. 4-4A).  IFN-γ, IL-12(p70) and IL-2 cytokine levels induced in lymph nodes of 
Group 1 mice were significantly highly than Group 2 mice and Group 3 (control) mice 
(Fig. 4-4B). With respect to the anti-mycobacterium cytotoxicity responses induced by 
activated lymphocytes post-vaccination, the colony counts were lowest in Group 1 mice 
upon co-culture with infected macrophages and this was significantly different from 
Group 3 (control) mice but was not significantly different from Group 2 mice (Fig. 4-4C). 
Therefore, we concluded that the sequential administration of two doses of Flt3L 
followed by peptide (Group 1) was more favourable than a scheme which attempts to 
intersperse the Flt3L administration with peptide vaccination (Group 2). Our results also 
indicate that the sequential administration of two doses of Flt3L before peptide improves 
the immune response of immunised mice (Group 1) compared to control mice immunised 











Figure 4-4: Optimisation of timing for peptide vaccination after Flt3L administration. A: 
Three groups of mice were given 75µg/dose Flt3L and 200 µg/dose RGD-Ag85B peptide 
(Ag) at different time points indicated by arrows. In group 3 (control) mice, no Flt3L was 
given. B: Cells from pooled brachial, axillary and inguinal lymph nodes were stimulated 
ex vivo with Ag85B peptide for 48 h and cytokine levels measured by ELISA. C: 
Mycobacterium killing assay was performed as described in Methods and number of 
viable BCG enumerated. Group means are depicted, error bars show ±1 S.D. * p< 0.05 
**p< 0.01 ***p< 0.001. 
 
 
4.4.5 Immunological effects of the vaccine  
 
Figure 4-5A shows the final immunisation schedule used for all subsequent 
experiments using the peptide vaccines. The BCG-immunised mice were only given a 
single dose of BCG, without Flt3L. To determine the number of antigen-specific cells 
induced by this immunisation scheme, lymph nodes from immunised mice were 
stimulated with Ag85B peptide and IFN-γ ELISPOT performed (Fig. 4-5B). The number 
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of Ag85B-specific immune cells was 11.5-fold higher in the RGDAg85B-immunised 
mice than the Ag85B-immunised mice. PBS mice gave negligible counts, showing the 































































































































IFN-γ responses to the vaccine peptide in the draining lymph nodes were 
significantly higher (2.4-fold) in RGD-Ag85B mice than Ag85B mice, but lower than 
BCG mice (Fig. 4-6A). IL-12(p70) production in lymph nodes showed a similar trend, but 
was generally low, and not statistically significant. IL-2 production was approximately 
10% higher in RGDAg85B mice than Ag85B mice, this was statistically significant but 






















Figure 4-5: Peptide vaccination
schedule and frequency of peptide-
specific cells induced. A: Mice
were immunised according to the
scheme depicted. Flt3L (75
µg/dose) was given
intraperitoneally and 200 µg of
either RGDAg85B or unmodified
Ag85B peptide antigen (Ag) in
TDB/DDA adjuvant was given
subcutaneously in the scruff of the
neck. Mice immunised with PBS in
adjuvant or with 5 × 105 live BCG
were used instead of Ag, as
negative and positive controls. All
mice were sacrificed 1 week after
the last dose of antigen was given.
B: Mice were immunised according
to the scheme depicted in A. LN
cells from pooled brachial and
axillary lymph nodes were
stimulated ex vivo with Ag85B for
48 h and IFN-γ ELISPOT was
performed. SFU = Spot forming
units (SFU). Results shown
represent three independent
experiments with each variable
assayed in duplicates. Group means
shown, error bars indicate ± 1 S.D. 
A 
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unremarkable. The proliferative response in immune cells from the lymph nodes of 
RGD-Ag85B mice was also significantly higher than the Ag85B mice, but the magnitude 
of this increase was small (Fig.4-6B).  
 
 
All immunised mice had higher T cell percentages in the spleen relative to PBS 
mice (Table 4-1). Both CD4 and CD8 proportions were higher in RGD-Ag85B mice, 
compared to the Ag85B mice, but a more substantial increase was seen in proportion of 























































Figure 4-6: Cytokine production 
and lymphocyte proliferation 
induced by peptide immunisation 
scheme. Mice were immunised 
according to the scheme depicted 
in fig. 4-5A. Mice immunised 
with PBS in TDB/DDA adjuvant 
formulation or with 5 × 105 BCG 
were, respectively, negative and 
positive controls. All mice were 
sacrificed 1 week after the last 
dose of antigen was given. A: LN 
cells from pooled brachial and 
axillary lymph nodes were 
stimulated ex vivo with Ag85B 
for 48 h and IFN-γ, IL-12(p70) 
and IL-12 levels were measured 
using ELISA. ND: Not detectable. 
B: The same set of LN cells was
stimulated ex vivo with Ag85B 
for 48 h and alamarBlue assay 
performed to investigate 
lymphocyte proliferation. All 
results shown represent three 
independent experiments, with 
each variable in triplicates. Group 
means are shown, error bars 
indicate 1 S.D. ND: Not 
detectable.
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the BCG mice (28%), and higher than the Ag85B mice (22%) but not statistically 
significant. There was no difference in the expression of CD62L in the lungs and spleens 
of the mice given different immunisations (data not shown).  
 
 
Table 4-1:  CD4 and CD8 T cell percentages induced by peptide immunisation scheme. 
Mice were immunised according to the immunisation scheme depicted in fig. 4-5A. Mice 
immunised with PBS in TDB/DDA adjuvant or with 5 × 105 live BCG were used as 
negative and positive controls, respectively. The percentage of CD4 and CD8 splenocytes 
were analysed by flow cytometery analysis. Percentages represent means of three 
experiments. *percentages of lymphocyte-gated splenocytes. 
 
 
In summary, the findings in this chapter are as follows. The Flt3L schedule chosen 
led to DC expansion in murine organs and sequential Flt3L and peptide administration 
improves immunogenicity over peptide alone. Based on the final immunisation schedule, 
RGD-Ag85B peptide was significantly better than the unmodified peptide, in terms of 
inducing antigen-specific IFN-γ producing cells in the draining lymph nodes, and 
increasing the proportion of CD4 and CD8 T cells in the spleen. The RGD-tagged vaccine 
also induced higher overall IFN-γ production in the lymph nodes, and a small increase in 
proliferative responses in the spleen. This demonstrates that the RGD-linked Ag85B 
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peptide was more effective in inducing cellular responses than unmodified peptide, in 




This work applies the RGD-peptide vaccine to in vivo immunisation, principally 
to investigate whether the integrin-targeting motif (RGD) added to a known Mtb 
immunogenic peptide (Ag85B100-118) would yield in vivo immunological effects that are 
superior to the unmodified peptide. This would form proof-in-principle that such a 
vaccination strategy may be worth exploring.  
The use of BCG to boost prior BCG-generated immune responses is not very 
successful (Leung et al. 2001), possibly because recall of BCG-specific memory 
responses reduces dissemination of the live BCG (Brandt et al. 2002). Although we have 
tested our peptide-based vaccine strategy only in naïve mice, there is also potential for 
this to be a booster or post-exposure vaccine in individuals with prior exposure to 
mycobacterial antigens, such as BCG-vaccinated persons or those with exposure to 
environmental mycobacteria or latent TB infections. Pre-exposure to environmental 
mycobacteria does not lead to a failure in induction of protective responses against Mtb in 
mice immunised with subunit vaccines (Brandt et al. 2002). This could be because cross-
reactive memory responses reduce multiplication of live vaccines like BCG, but should 
only serve to boost T cell responses to shared proteins included in the subunit vaccine. 
For this reason, the Ag85B protein which is shared among Mtb, M. bovis BCG and 
various other species of mycobacteria (Harth et al. 1996) was chosen for our vaccine, 
instead of Mtb-specific proteins. 
In the experiment without Flt3L (Fig. 4-3A), RGD-Ag85B immunisation alone 
induced better T cell IFN-γ production in the lymph nodes than unmodified Ag85B, 
providing the first indication that attachment of the RGD motif to Ag85B increases 
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in vivo cellular immune responses. To further augment the response, the Flt3L 
administration strategy was added to expand DCs before antigen introduction. A study 
administering Flt3L (up to 100 µg/ kg/day) for 14 consecutive days to human patients 
reported no side effects (Maraskovsky et al. 2000). However, we were conscious of the 
need to minimise the quantity used and dosing frequency, to simplify the logistics of 
administering this vaccine schedule  hence, dose optimisation was performed. We were 
also concerned whether the route of Flt3L administration may result in enhancement of 
DC numbers in specific localised tissues/organs since our vaccine would be introduced 
via the subcutaneous route. However, studies which have used consecutive daily 
injections of Flt3L via the subcutaneous or intraperitoneal route have both reported 
enhancement of DCs in a variety of different organs (Brasel et al. 1996; Maraskovsky et 
al. 1996; Furumoto et al. 2004; Masten et al. 2004), and showed that both subcutaneous 
and intraperitoneal administration of Flt3L leads to a systemic enhancement of DC. In 
this project, we have chosen to administer Flt3L via the intraperitoneal route. Although 
scheme 2 (daily dosing) increased the proportion of DCs in the spleen most significantly, 
Scheme 3 with two doses of 75 µg Flt3L was chosen for the best levels of DC expansion 
in the lungs and reasonably good levels in the spleen, both achieved with minimal number 
of doses. Additionally, we were concerned about the state of maturity of DCs at the point 
of antigen introduction, because only immature DCs can optimally take up antigen 
(Lanzavecchia 1999; Steinman et al. 1999). It is not clear whether administering 10 µg 
Flt3L consecutively for 9-10 days generates DCs of a mature or immature phenotype, as 
there are conflicting reports. In mice given 10 µg Flt3L consecutively for 10 days, CD8+ 
and CD8- DC isolated are predominantly immature cells (CD40low, CD86low, and MHC 
class IIlow), with a minor population of mature DC (O'Connell et al. 2000). However, 
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another study with a 9-day consecutive dosing schedule observes development of 
functionally mature DCs (Maraskovsky et al. 1996). To avoid having mature DCs at the 
point of antigen introduction, we sought to introduce the peptide as soon as possible after 
initial Flt3L-induced differentiation of DCs, and this was another reason for choosing to 
introduce antigen at day 5 after Flt3L at day 0 and day 3 (Fig. 4-2A), rather than the 9  
10 day Flt3L dosing schedule favoured by some other studies. 
Although correlation between vaccine effectiveness and the levels of specific 
cytokine responses is not guaranteed, there have been several studies showing this is true 
(Goonetilleke et al. 2003; Dietrich et al. 2005; Grover et al. 2006; Teixeira et al. 2006). 
Several authors have suggested that post-vaccination induction of lymphocytes producing 
IFN-γ in response to TB-specific antigen(s) might be used as a correlate of protection 
(Martin et al. 2000; McMurray 2001; Baumann et al. 2006). Th1 type responses are  
required for the control of tuberculosis, since murine and human studies suggest that 
deficiency in IFN-γ and IL-12 production increases susceptibility to mycobacterial 
infections (Flynn et al. 2001).  Although some studies fail to find a correlation between 
IFN-γ production and TB protection (Li et al. 1999), the general consensus remains that 
antigen-specific IFN-γ production is the most likely indicator of vaccine induced 
resistance (McMurray 2001).   
The RGD-Ag85B peptide significantly increased both absolute IFN-γ production 
(Fig. 4-3A, 4-6A) as well as the frequency of IFN-γ producing, epitope-specific cells 
(Fig. 4-5B) in lymph nodes of immunised mice, compared to unmodified Ag85B peptide. 
The epitope-specific cells were particularly increased by a large margin (11.5-fold) over 
unmodified peptide.  We consider this to be the most important and significant aspect of 
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our vaccination strategy. There is evidence that vaccines eliciting high frequencies of 
antigen-specific T cells capable of IFN-γ production are associated with better protection 
from Mtb challenge (Malowany et al. 2006). In our study, the RGD-Ag85B vaccine 
elicited an Ag85B100-118 specific T cell response of 115 SFU/million cells in draining 
lymph nodes (Fig. 4-5B). This level of response is comparable with other subunit vaccine 
strategies which used whole recombinant proteins. For example, mice immunised with 
modified vaccinia virus Ankara expressing whole recombinant Ag85A, or with 107 BCG, 
have Ag85A-specific IFN-γ CD4 T cell responses of approximately 100 SFU/million in 
draining lymph nodes (Goonetilleke et al. 2003). A mucosal vaccine introducing the 
recombinant Ag85B-ESAT-6 fusion protein intranasally yields approximately 
200 SFU/million antigen-specific cells in the spleen after in vitro restimulation with 
Ag85B-ESAT-6 protein (Dietrich et al. 2006). Thus, our single peptide vaccine, based on 
our immunisation strategy, yielded levels of epitope-specific protective cells equivalent to 
whole recombinant protein vaccines. This may be attributable to the DC-targeting of the 
peptide vaccine, since similar levels could not be achieved with unmodified peptide (Fig 
(Fig. 4-5B). 
In contrast to the good IFN-γ response, we did not find a very large increase in 
antigen-stimulated IL-2 production by our vaccine (about 100 pg/ml, Fig 4-6A). This 
level of IL-2 induction is comparable with another peptide vaccine study investigating 
subcutaneous 10 µg Ag85B240-254 in incomplete Freund's adjuvant in C57BL/6 mice, 
which reports that peptide restimulation of lymph node cells for 4 days produced a mean 
IL-2 level of 35 pg/ml (Kariyone et al. 2003). In contrast, a study on Ag85B DNA 
vaccination of Balb/c mice shows mean splenocyte IL-2 levels of approximately 
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15,000 pg/ml, after 24-hour re-stimulation with Ag85B100-117 (D'Souza et al. 2003). IL-2 
promotes the survival and differentiation of activated T cells into armed effector T cells 
(Naik et al. 2005). Thus, we used IL-2 production as an indirect indicator of whether 
immunisation clonally expanded and proliferated T cells recognising the vaccine epitope. 
The modest induction of IL-2 by our vaccine was associated with a corresponding small 
increase in proliferative response of lymphocytes in RGD-Ag5B immunised mice (Fig. 
4-6B). There was also a parallel increase in the proportions of CD4 and CD8 cells in the 
spleens of RGD-Ag85B immunised mice (Table 4-1). Taken together, these results 
indicate that immunisation with RGD-Ag85B induced modest expansion of epitope-
specific T cells, thereby increasing the population of T cells capable of initiating an 
adaptive response rapidly after pathogen encounter. This is an encouraging result since a 
study using a recombinant Ag85B fusion protein vaccine demonstrated that high levels of 
antigen-specific CD4 and CD8 T cells are associated with protection against Mtb in the 
lungs (Tang et al. 2008).  
In GM-CSF differentiated DCs, we showed that more αvβ3 integrin-expressing 
DCs took up the RGD-peptides than the unmodified peptide, whereas the integrin-
negative DCs did not show any difference in uptake of the two peptides Thus, the 
attachment of the RGD motif to the Ag85B peptide is associated with better Ag85B 
peptide uptake, most likely through integrin-targeting. However, integrins are not 
DC-specific. Unlike studies targeting vaccines specifically to DC receptors, such as 
DC-SIGN (Tacken et al. 2005) and DEC-205 (Badiee et al. 2007), the use of RGD in our 
approach could potentially result in binding of the peptide to any cell expressing integrins 
such as α1β1, α2β1, α5β1 and αvβ3 (Kim et al. 2007). However, preferential uptake by DCs 
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is likely with subcutaneous vaccination because of their localisation (Shortman et al. 
2007) and on average, there is higher expression of these integrins on human immature 
DCs than macrophages (Albert et al. 1998; Ammon et al. 2000).  
  A TB vaccine strategy which also used a combination of Flt3L and Ag85B was 
investigated recently, in the form of a DNA vaccine encoding both elements as a fusion 
(Triccas et al. 2007). This study provides evidence of better protection against Mtb 
challenge with the Flt3L-Ag85B fusion DNA vaccine than Ag85B alone, and even Flt3L 
DNA vaccine conferred some non-specific protection. However, in our strategy, we chose 
to simply inject the Flt3L directly into the host as it has proven safety and efficacy in 
humans (Maraskovsky et al. 2000), relative to DNA vaccines (Glenting et al. 2005). With 
our strategy, in spite of using only a single peptide epitope, the antigen-specific IFN-γ 
levels elicited were 5-fold higher than observed with the Flt3L-Ag85B DNA vaccine. 
Ex vivo antigen-pulsing of DCs as a vaccine strategy has been applied in research on 
infections including Lyme disease (Mbow et al. 1997), Chlamydia trachomatis (Su et al. 
1998), lymphocytic choriomeningitis virus (Ludewig et al. 1998), Candida albicans 
(d'Ostiani et al. 2000) and Leishmania major (Flohe et al. 1998) infections. For example, 
a single treatment with parasite lysate-pulsed DCs is sufficient to induce protection 
against rechallenge with Leishmania parasites (Flohe et al. 1998), demonstrating the 
importance of DC recognition of parasite antigens in protective outcomes. In TB studies, 
ex vivo DCs pulsed with Ag85 antigens as a murine vaccine has not been very successful 
in protecting against pulmonary Mtb challenge (Gonzalez-Juarrero et al. 2002), perhaps 
an adjuvant may be required in this case.  The key consideration, however, is that he 
logistics of ex vivo sterile DC isolation, culture and reintroduction into the host make this 
resource-intensive approach impractical for mass vaccination in rural communities of 
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developing nations where the TB vaccine is most needed. In comparison, the strategy we 
propose for direct in vivo DC targeting is relatively simpler and much less labour-
intensive. 
Although we did not show the outcomes of a mycobacterium challenge study in 
this thesis, this has already been demonstrated in my previous work (unpublished). We 
conducted a previous study immunising mice twice subcutaneously 1 week apart with 5 
mg/ml of Ag85B or RGD-Ag85B peptide in 15% v/v alum adjuvant formulation, 
followed by intranasal challenge with 2 × 106 CFU of BCG 1 week after immunisation. 
The result showed that RGD-Ag8B but not Ag85B produced significant increase in IL-2 
production over control (PBS) immunised mice, with significant increase in the 
recruitment of T cells to the infection site and associated reduction in bacterial load in the 
lungs after infection. Hence, the vaccine strategy has already been shown to be promising 
in protection against mycobacterium challenge. The main objective of this thesis was to 
establish in detail how the RGD-peptide differed from the unmodified peptide in specific 
immunological effects.  
A simple linear RGD-Ag85B peptide was used in this study because it is 
technically easy to synthesise reproducibly and rapidly, thus production of such a vaccine 
would be relatively inexpensive. However, linear RGD-peptides are more susceptible to 
chemical degradation due to the reaction of the aspartic acid residue (D) with the peptide 
backbone (Bogdanowich-Knipp et al. 1999). Rigidity in the RGD-peptides contributes to 
achieving the right conformation which will increase the affinity of the peptide to the 
integrin, therefore a cyclised structure (Pierschbacher et al. 1987) for RGD-peptide 
vaccines may be better.  Whether it will confer any improvements in immunological 
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profile should be explored in future studies, as the RGD-mediated DC targeted peptide 
vaccine strategy shows promise in improving the immunogenicity of peptide subunit 
vaccines for TB.  
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Chapter 5: Final discussion and future work 
  
Different subtypes of DCs are associated with different functional capabilities. For 
example, dermal DCs have been implicated in the generation of cellular immunity 
(Filippi et al. 2003; Itano et al. 2003; Von Stebut et al. 2003; Zhao et al. 2003), and have 
been identified as the critical cell type required for sustained CD4 T cell priming and 
expansion when a protein antigen is injected (Itano et al. 2003). In future work, we could 
investigate which subtype of DCs have increased uptake of the RGD-Ag85B peptide in 
the mouse after vaccination, and examine whether the subtypes are different from those 
taking up unmodified peptide. Phenotyping the DCs which take up the peptide in vivo 
would require conjugation of the peptide to a very stable fluorochrome that maintains its 
intensity in vivo. A possible fluorochrome that is stable at a wide range pH and can be 
used for cell labeling is the 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) 
fluorochrome from Molecular Probes (Hama et al. 2006). If two different fluorochromes 
are used for the unmodified and RGD-peptides, then the peptide-containing DCs could be 
tracked from skin to draining lymph nodes and differentially phenotyped. Whether RGD 
conjugation leads to differential in vivo migration could also be assessed concomitantly, 
as our current work only examined this in vitro. 
Our study indicates that the DC-targeting strategy of attaching the RGD motif to 
peptide Ag85B100-118 and introducing it with a Th1 polarising adjuvant (TDB/DDA), 
coupled with prior Flt3L administration to expand the DC population, results in 
significant overall improvement in antigen-specific responses in mice, relative to the 
unmodified peptide. In terms of the frequency of peptide-specific, IFN-γ producing T 
cells, the magnitude of responses was quite comparable with existing vaccine candidates 
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in clinical trials. However, the ability to induce lymphocyte proliferation and other 
cytokine production was not substantial, perhaps this could be improved by modifying 
some aspects of the vaccination strategy. Three aspects come to mind. First, the adjuvant 
used needs to be optimised  adjuvant modifications have a profound impact on 
protective outcomes of subunit vaccines (Agger et al. 2008). It has been recently found 
that a strong Th1 polarising adjuvant  dimethyl dioctadecyl ammonium bromide 
/monophosphoryl lipid A (DDA/MPL)  gives the best outcome in terms of induction of a 
high level of IFN-γ coupled with an accelerated recruitment of IL-17 and IFN-γ-
producing lymphocytes essential for the formation of granulomas containing clustered 
inducible nitric oxide synthase-activated macrophages.  Another adjuvant that has been 
used in TB vaccine studies is the IC31 adjuvant system, which is a combination of an 
antimicrobial poly-peptide (KLKL5KLK) and a phosphodiester-backboned 
oligodeoxynucleotide (ODN1a) which has been shown to induce potent cell-mediated 
responses characterised by the generation of high numbers of IFN-γ secreting cells 
(Kritsch et al. 2005; Schellack et al. 2006). Use of IC31 adjuvant with Ag85B-ESAT-6 
fusion protein gives efficient protection in the TB infected guinea pig (Agger et al. 2006).  
Although there is no single immunological measurement that has ideal reliability 
in quantitative prediction of the level of protection induced by a TB vaccine in an 
immunised host, there is general agreement in the field with regards to possible 
immunological indicators that could be suggest immune protection. In view of the 
substantial evidence for the crucial role of IFN-γ in TB protection, the ability of 
lymphocytes from an immunised individual to produce a TB antigen-specific IFN-γ 
response is often the main correlate of protection studied (Martin et al. 2000). Another 
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parameter that has been suggested as a possible immunological indicator of TB protection 
is the capability of lymphocytes from immunised individuals to activate autologous 
macrophages in vitro to prevent the intracellular growth of Mtb (Dai et al. 1998; Silver et 
al. 1998). However, assays of this nature are complex and have not been examined widely 
in different types of animals immunised with a range of vaccines (McMurray 2001). The 
generation of a significant population of memory T cells specific for an immunogenic TB 
antigen is also required for long term vaccination-induced resistance. In murine models, 
these memory cells have a distinct phenotype and are associated with protection of naïve 
recipient mice from virulent Mtb challenge (Andersen et al. 2000).  
The relevance of each of these correlates of protection has been tested in a recent 
study examining the same Ag85B-ESAT-6 fusion subunit vaccine with a variety of 
adjuvants (Agger et al. 2008) in the context of cellular response induced, bacterial 
replication and pathology in Mtb-infected murine lungs. The vaccine in Th1-polarising 
adjuvant DDA/MPL shows the best protection against Mtb challenge, compared to the 
mixed Th2-Th1 polarising adjuvant aluminium hydroxide/DDA and the Th2-polarising 
adjuvant aluminium hydroxide. In this study, vaccine protection correlates with the 
magnitude of IFN-γ response induced, and accelerated recruitment of IFN-γ producing T 
cells to the site of infection. Notably, even if a Th2-polarising adjuvant is used, as long as 
the IFN-γ production is substantial, the mice are still protected against Mtb (Agger et al. 
2008). The expansion of T cell populations leading to an accelerated accumulation of 
lymphocytes at the infection site and accelerated granuloma formation are also suggested 
to be important features of post-vaccination protective immunity in TB (Andersen et al. 
1995; Ordway et al. 2006; Agger et al. 2008). The vaccine strategy described in this thesis 
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could be considered promising as it fulfilled at least two of the key immune correlates of 
protection considered important in the field.    
In future work, the Flt3L immunisation scheme may require further optimisation 
with monitoring of the extent to which in vivo immature DCs are generated. Additionally, 
modifications to the manner of conjugating the RGD motif to the epitope Ag85B100-118 
and/or creating RGD-peptide multimers may be tested to determine if further 
enhancements to DC targeting could be achieved. The conformation of RGD-conjugated 
peptides and proteins is determined by other amino acid residues flanking the RGD-motif, 
in particular the two positions following the aspartic acid (Pierschbacher et al. 1987). The 
flanking groups of the RGD motif influence peptide folding and thereby the conformation 
of the subunit vaccine. For the RGD-peptide to bind strongly to the integrin receptor, it 
has been suggested that rigidity in structure is important. Some groups have investigated 
the use of the RGD motif to improve binding of proteins to cells via the integrin motif 
(Dechantsreiter et al. 1999; Janssen et al. 2002), using a cyclised structure of the 
RGD-peptide. We chose to use a linear RGD-peptide because this is technically less 
challenging to synthesise, and if effective, would have the lowest production cost. To 
improve the targeting of our peptide vaccine to DCs, it may be necessary to employ a 
cyclic peptide structure containing the RGD motif (Dechantsreiter et al. 1999). A phage 
display approach may be relevant in helping us to determine which cyclic structure of our 
RGD-peptide has the highest affinity and selectivity for DCs. This approach has been 
successfully applied to generate a RGD-peptide ligand RGD4C which contains two 
disulfide bonds and has a 20-fold increased potency compared to similar peptides with a 
single disulfide bond and a 200-fold increased potency compared to linear peptides 
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(Koivunen et al. 1995). Modifications of the peptide with non-natural amino acids or 
substitutions with peptidomimetic structures are other alternatives to achieve increased 
specificity and affinity (Goodman et al. 2002). Another approach that could be used to 
improve the targeting of our peptide vaccine to DCs is to construct a multimeric RGD 
peptide, involving the addition of multiple RGD moieties in the linear peptide in an 
optimal spatial alignment. A study using this approach reports that multimeric RGD 
compounds have increased binding affinity and higher endocytosis by tumour cells 
compared to their monovalent analogues (Ye et al. 2006).  
After modifications to our present vaccine strategy, murine challenge studies with 
live Mtb via the aerosol route should be performed, to look for improvements in reduction 
of bacterial load in the organs. However, it is also clear that murine studies do not 
necessarily reflect human outcomes in tuberculosis as the mouse is not a natural host 
(Sander et al. 2007).  Therefore, the sensitivity of the murine model is limited due to an 
inherent threshold of protection, making discrimination between the protective efficacy of 
very similar vaccines difficult (Sander et al. 2007). Another major disadvantage of the 
murine model is that the pathology induced by Mtb infection is distinct from humans, 
granuloma formation is less organised, and the granulomas do not develop necrosis unlike 
in the human host. Several direct comparisons of vaccination outcomes between human 
and murine studies have already shown divergent results. Recombinant modified vaccinia 
virus Ankara (MVA) expressing antigen 85A (MVA85A) induces high levels of antigen 
specific IFN-γ secreting cells when used alone in BCG-naïve human volunteers. In those 
with prior BCG immunisation, the levels are increased 5-30 times more than those given 
a single BCG vaccination (McShane et al. 2004). However, in the murine model, 
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intranasal administration of BCG followed by a booster vaccine of MVA85A given 
intransally induces levels of antigen specific IFN-γ secreting cells that are merely 3-5 fold 
higher than mice receiving BCG only (Goonetilleke et al. 2003). In another study, Balb/c 
mice given two immunisations of BCG either parenterally or intranasally have better 
protection against Mtb challenge, compared to mice given only one immunisation 
(Goonetilleke et al. 2003). However, in humans, repeated intradermal BCG immunisation 
does not increase protection against pulmonary TB over those receiving a single 
immunisation (Karonga Prevention Trial Group 1996). These examples underscore the 
difficulties in interpretation which may arise in conducting vaccine studies with Mtb 
challenge in mice. 
Despite these disadvantages associated with the murine model of TB, it still 
remains the most widely used model in the evaluation of vaccine candidates because this 
model is cheap and relatively short-term in the context of this chronic infection (Sander et 
al. 2007). It is also possible to investigate the immunological mechanisms which are 
responsible for the protection conferred by the vaccine because of the wide availability of 
immunological reagents (Sander et al. 2007). The alternative of using non-human 
primates in TB vaccine studies is costly and numbers of animals used is necessarily 
limited, but the immune responses are more likely to be consistent with the human 
situation.  
An important advantage of our subunit vaccine strategy is that most of the 
adjuvants under consideration and Flt3L have been used in clinical trials with proven 
safety. Therefore, there should be minimal obstacles to bringing this vaccine into human 
trials, in contrast to other live vaccine or DNA vaccine approaches. Our vaccine could 
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first be tested as a booster vaccine in an adolescent prime-boost clinical trial based on a 
population with an established routine of BCG vaccination in infancy, to determine 
whether the protection may be extended into adulthood. For a trial of primary 
vaccination, replacement of a century-old vaccine requires careful consideration. Human 
studies on using this vaccine to replace BCG totally could potentially first be carried out 
in areas where the standard practice is not to administer BCG till adolescence and/or areas 
where clinical trials have proven BCG to be ineffective. Clinical trials on this vaccine 
could also be considered in lieu of BCG in the immunocompromised since live vaccines 
cannot be administered safely in this group.  In each of these scenarios, follow-up 
annually to look for occurrence of active TB as a clinical end-point is likely to require 
about 10 years (Doherty 2005), even in areas with high endemicity. Trials could also be 
conducted with TB contacts diagnosed with latent tuberculosis infection (as a 
post-exposure vaccine) to determine if the rate of reactivation could be reduced, but the 
vaccine-attributable effect is likely to be very small unless it is used in place of, rather 
than concurrently with, chemoprophylaxis. However, those who are unable to tolerate TB 
antibiotics could be enrolled in a trial of post-exposure vaccination. The effects of prior 
exposure to environmental mycobacteria on efficacy of this vaccine also need to be 
assessed in those populations where such exposure has been proven to be highly prevalent 
(Karonga Prevention Trial Group 1996). This would require administration of this 
vaccine or BCG (control) to adolescents or adults in these areas, to determine if the 
vaccine is superior to BCG in this epidemiological setting. 
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Chapter 7: Appendix 
 
7.1 Flt3L (Fms-like tyrosine kinase 3 ligand) production and purification  
 
CHO-K1 cells containing a plasmid coding for recombinant FLAG-tagged murine 
Flt3L were generously donated by Dr Wilson of WEHI, Australia. They were cultured in 
75cm2 flasks in passage medium (RPMI-5 supplemented with 400 µg/ml of G418) until 
they reached confluence. The cells were reseeded in 150 cm2 culture flasks in expansion 
medium (RPMI-2) and allowed to proliferate for 6  7 days before the supernatant was 
harvested. Protein purification was achieved with the Anti-FLAG M2 Affinity Gel 
column (Sigma).  
 
7.2 Western blot  
 
Purified supernatants containing the putative Flt3L were denatured at 95 °C for 
5 min in 4 × Sodium Dodecyl Sulfate (SDS) loading buffer (Invitrogen).  Five microlitres 
were loaded in a sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) gel and electrophoresis performed at 100 V in an electrophoretic cell (Mini-
Protean 3 Cell, Bio-Rad) for 1.5 h. The gel was transferred onto a polyvinylidene fluoride 
(PVDF) membrane (Invitrogen) using the iBlot Gel transfer system (Invitrogen). The 
membrane was treated with blocking buffer containing 3% low fat milk at room 
temperature for 1 h before rinsing with 0.5ml of TBST (Tris-buffered saline with 0.05% 
Tween 20) /cm2. Subsequently, the membrane was incubated with M2 FLAG monoclonal 
antibody (Sigma) at a final concentration of 10 µg/ml, overnight at 4 °C. The membrane 
was then washed 4 times with 0.5 ml of TBST/ cm2  and then incubated with goat 
anti-mouse IgG alkaline phosphatase conjugate (Chemicon) at a 1:1000 dilution. After 
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further washing three times with TBST and once with PBS, sufficient BCIP/NBT 
Phosphatase substrate (5-bromo-4-chloro-3-indolyl-phosphate/nitroblue tetrazolium) 
(Chemicon) was added to cover the membrane for 10  15 min incubation at room 
temperature to allow colour development, before terminating the reaction with multiple 
rinses with distilled water. Met-FLAG-BAP protein-N-terminal Met-FLAG fusion protein 
of E. coli bacterial alkaline phosphatase (BAP) was used as a positive control. Cell 
supernatant that passed through the purification column was used as a negative control. 
 
7.3 Preparation of TDB/DDA (trehalose 6, 6'-dibehenate/ dimethyl dioctadecyl 
ammonium bromide) adjuvant  
 
DDA was dissolved with sterile nanopure water to a concentration of 2.5mg/ml 
and then heated to 80°C with continuous stirring for 20 minutes, and cooled to room 
temperature before use. TDB was dissolved with sterile nanopure water containing 2% 
DMSO (dimethyl sulfoxide) to a concentration of 5 mg/ml by repeated passage through a 
fine-tipped pipette followed by 30 sec of vortexing. This step was repeated thrice before 
freezing at -20°C until use. The final adjuvat formulation required for immunisation was 
prepared by mixing 250µg of DDA and 300 µg of TDB using vigourous pipetting to 
achieve a homogenous mixture just before immunisation.  
 
7.4 Preparation of Tris-buffered saline with 0.05% Tween 20 (TBST) 
 
25 mM Tris-HCl, 
 125 mM Sodium chloride, 
0.1% Tween-20.  
The above components were added and adjusted to a final pH of 8.0. 
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7.5 Preparation of sodium dodecyl sulfate polyacrylamide (SDS-PAGE) gel 
 
 Resolving Gel Stacking Gel 
 12.0% in 0.5 M Tris-HCl 
pH 8.8 
3.9% in 0.125 M Tris-HCl 
pH 6.8 
Sterile water 6.6 ml 6.1 ml 
30% bis-acrylamide stock 8.0 ml 1.3 ml 
Tris-HCl 
(Tris-Hydrogen Chloride) 
5.0 ml of 1.5 M Tris-HCl 
pH 8.8 
2.5 ml of 0.5 M Tris-HCl 
pH 6.8 
10% SDS 
(Sodium dodecyl sulfate) 
200 µl 100 µl  
10% APS 
(Ammonium persulfate) 
200 µl 100 µl  
TEMED 
(Tetramethylethylenediamine)
8 µl 10 µl 
Total volume 15 ml 10.1 ml 
Components were added in the given order in the table, with TEMED added just before 
gels were casted.  
 












1 L 900 ml 4.7 g 10 ml 5 ml 100 ml 
All ingredients were added aseptically to the prepared culture media and autoclaved at 
121 °C for 15 min. OADC was added only before use.  
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1 L 900 ml 19 g 10 ml 5 ml 100 ml 
All ingredients were added aseptically to the prepared culture media and autoclaved at 
121 °C for 15 min. The agar media was left to cool to 60 °C before OADC was added and 
the liquefied agar aliquoted into petri dishes and allowed to set. 
